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List of symbols and abbreviations 
 
CePC-HSA                      Cetuximab modified mTHPC-HSA nanoparticles 
CNPL1, 2, 3                     mTHPC-PLGA nanoparticles with different loading ratios 
CoPC-HSA                      Covalently binding mTHPC-HSA nanoparticles 
D2O                                  Deuterium oxide 
fET                                     Energy transfer efficiency factor 
FWHM                             Full width at half maximum 
HpD                                  Hematoporphyrin Derivates  
HSA                                  Human Serum Albumin nanoparticles 
HLPP-HSA                       High loading ratio mTHPP-HSA nanoparticles 
IC                                      Internal Conversion 
IgGPC-HSA                      IgG modified mTHPC-HSA nanoparticles 
ISC                                    Inter-System Crossing 
LLPP-HSA                        Low loading ratio mTHPP-HSA nanoparticles 
Mol, M                              Molar, Molar / Liter 
mTHPC                              5, 10, 15, 20-Tetrakis (3-hydroxyphenyl)-chlorin 
mTHPC-PLGA                   mTHPC loaded PLGA nanoparticles 
mTHPP                               5, 10, 15, 20-Tetrakis (3-hydroxyphenyl)-porphyrin 
mTHPP-COOH                  5-(4-Carboxyphenyl)-10, 15, 20-tris (3-hydroxyphenyl)- 
                                                 porphyrin 
mTHPP-PLGA                   mTHPP loaded PLGA nanoparticles 
NP                                       Nanoparticle 
NPC                                    mTHPC-HSA nanoparticles with different cross-linkages 
NPL1, 2, 3, 4, 5                  mTHPC-HSA nanoparticles with different loading ratios 
OD                                      Optical Density 
OPO / OPA                         Optical Parameter Oscillator / Optical Parameter Amplifier 
PDT                                     Photodynamic Therapy 
PEG                                     Polyethylene glycol 
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Pheo                                     Pheophorbide a 
PHSA40                              40% cross-linked Pheo-HSA nanoparticles 
PHSA100                             100% cross-linked Pheo-HSA nanoparticles 
PLGA                                   Poly (D,L lactide-co-glycolide) nanoparticles 
PNPL1, 2, 3                          mTHPP-PLGA nanoparticles with different loading ratios 
PS                                         Photosensitizer 
TCSPC                                 Time-Correlated Single Photon Counting 
TPPS                                  5, 10, 15, 20-Tetraphenyl-21H, 23H-porphine-p, p’, p’’, 
p’’’-tetrasulfonic acid, tetrasodium salt hydrate 
     , 1O2                                  Singlet oxygen 
ε                                             Extinction coefficient 
Φ∆                                          Singlet oxygen quantum yield 
ΦFL                                         Fluorescence quantum yield 
τ∆                                            Singlet oxygen lifetime 
τTair                                         Triplet lifetime under normal air condition 

















Photodynamic Therapy (PDT) is an effective treatment for a number of malignant and 
non-malignant tumours [Röder 2000]. PDT treatment is based on the presence of a 
drug with photosensitizing properties combined with visible or far red light and 
oxygen. In darkness PDT drugs are no or low toxic. Absorption of light with suitable 
wavelength by the tumour-localized sensitizer molecules leads to the generation of 
singlet oxygen, which directly or indirectly destructs tumour tissue. Tumour 
destruction can be realized both by cell death and by photodestruction of the tumour 
vasculature resulting in local hypoxia and indirect cell death [Dougherty et al 1998, 
Henderson et al 1992]. Targeting to tumour vasculature can also starve tumour by 
cutting oxygen-carrying blood supply. Within a few hours after successful PDT 
tumour tissue exhibits extensive regions of necrosis and apoptosis. These cell death 
mechanisms as well as inflammatory and immune responses are all induced by PDT 
[Brown 2004]. 
It is necessary to increase the selectivity of photosensitizer to tumour tissue or cells 
[Jux and Röder 2009]. This selectivity provides enhancement of therapeutic effect 
meanwhile minimizes the side effects of PDT. Targeting drug carriers under 
investigation include proteins, peptides, antibodies, liposomes, micelles, and polymers. 
Among these carriers, nanoparticles are regarded as a potential PDT agent carrier 
because of their high stability; high carrier capacity; feasibility to carry both 
hydrophobic and hydrophilic agents [Gelperina 2005]; multiple administration 
methods (oral or injection). Besides these advantages, nanoparticles can be designed 
as controllable drug release carriers.  Especially, nanoparticles with suitable size 
accumulate in tumour tissue because of the enhanced permeability and retention (EPR) 
effect (details see chapter 2). Moreover targeting antibody modified nanoparticles can 
identify tumour cells. 
Due to their relatively small size about 3-5 nm, inorganic nanoparticles such as gold 
and silica nanoparticles exhibits weak EPR effect. At the same time, they are easily to 
form aggregates in aqueous solution. Until now no appropriate inorganic 
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nanoparticles for PDT are found [Jux and Röder 2009]. For a long period many 
achievements in the field of biodegradable nanoparticles and their conjugations with 
photosensitizers have been published. In the relevant field, several works have been 
reported. For instance, meso-tetra (hydroxyphenylchlorine) (mTHPC) were loaded on 
biodegradable nanoparticles using passive targeting strategy and tested in HT-29 cells 
[Bourdon 2000]. 
Among numerous biodegradable nanoparticles, two types of nanoparticles earn 
widely concern. HSA protein nanoparticles are prepared and studied since they are 
biodegradable, non-antigenic, and controllable size distribution [Langer 2000]. PLGA 
nanoparticles have long been studied as controlled release drug carrier because of 
their biodegradability and biocompatibility [Bozkir 2005]. 
 
This PhD work is a part of a scientific network “NanoCancer” project. The eventual 
objective of this project is to develop a series of novel nanoparticle-basing drug 
delivery systems, which attain targeting effects to cancer tissue actively or passively. 
The highlight of innovation of this project is the combination of large drug carrying 
capacity with enhanced tumour targeting effect. 
Based on this idea, the goals of the work are set as: 
a. The selective accumulation of photosensitizer in targeting tumour tissues should be 
increased; 
b. The toxicity of photosensitizer-carrier system, especially singlet oxygen generation 
during drug administration should be minimized; 
c. Controllable and rapid drug release from the carrier should be achieved; 
d. Photosensitizer’s photo-activity won’t lose after drug release. 
 
In order to achieve these goals, the main tasks consist of: 
a. Photophysical characterizations of photosensitizer-nanoparticle carrier systems 
using absorption, steady-state fluorescence and TCSPC. 
b. Singlet oxygen quantum yield of photosensitizer-loaded nanoparticle formulations 




Interactions between photosensitizer molecules and nanoparticles are investigated. 
The influence of the antibody surface modification on singlet oxygen generation of 
photosensitizer-loaded nanoparticles is studied. 
 
The structure of whole PhD thesis is as follow: 
Chapter 0 is introduction. Brief history of PDT, basic principles of photosensitization 
and singlet oxygen as well as photosensitizer are given in Chapter 1. Principles of 
passive and active tumour targeting strategies are introduced in Chapter 2. The 
background knowledge of biodegradable nanoparticles is also provided in this chapter. 
All experiment techniques involved in this thesis can be found in Chapter 3. Chapter 4 
contains knowledge of used materials: photosensitizers and nanoparticles. Pheo-HSA 
nanoparticles as starting carrier system are investigated also in Chapter 4. In chapter 5, 
the influences of drug loading ratio and preparation process on the efficiency of 
mTHPP- and mTHPC-HSA nanoparticle systems according to efficient release of drug 
molecules are evaluated. The photoinduced singlet oxygen generation in solution and 
in cell suspension are studied. 
Chapter 6 focuses on the issue of PLGA nanoparticles as biodegradable carrier for 
PDT. The comparison of HSA and PLGA nanoparticles both in solution and in cell 
suspension is provided in Chapter 7. 
As active tumour targeting strategy, the surface modification with antibodies and PEG 
shell to nanoparticles is evaluated by intracellular singlet oxygen determination in 
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1. Brief history of Photodynamic Therapy and fundamentals of 
Photosensitization 
1.1 Brief history of Photodynamic Therapy 
Although practiced in ancient Egypt, India, and China thousands of years ago, using 
light and dyes under the presence of oxygen to produce cytotoxicity was pioneered by 
Oscar Raab, a student of Hermann von Tappeiner. Raab reported that paramecia could 
be killed by acridine after illumination. Based on Raab’s work, von Tappeiner and 
Jesionek described the first clinical trial of photosensitizer eosin on several skin 
tumours in the presence of light [von Tappeiner and Jesionek 1903]. 
Studies on photodynamic therapy (PDT) have become popular again based on two 
developments. Advancements in laser light sources and optical fibers have provided 
broad prospects for clinical PDT, not only for skin diseases but also for diseases 
associated with the visceral cavity. Suitable photosensitizers were discovered due to 
the contribution of a series of investigations by T. J. Dougherty and his group since 
1973. Their efforts have brought PDT from the laboratory into the clinic. Some of the 
basic principles have also been established to explain the mechanisms of PDT. 
Since 1973, numerous clinical PDT treatments have been geared towards lung cancer 
[Kato 1998], cancer of the gastrointestinal tract [Puolakkainen 1992, Moesta 1995], 
tumours in the head and neck regions [Bellnier 2003, Prosst 2003, Dilkes 2003], 
bladder [Jichlinski 2001] and prostate cancer [Nathan 2002]. PDT provides a method 
with fewer side effects compared with radiotherapy and chemotherapy; therefore, it 
offers doctors a possible choice for pre-cancerous disorders. For example, 
aminolaevulinic acid (ALA) PDT treatment for cervical and vulvar intraepithelial 
neoplasias has been reported [Barnett 2003, Keefe 2002]. In advanced cancer 
treatment, PDT improves quality of life. For instance, patients suffering from 
obstructing endobronchial non-small-cell lung cancer have exhibited increased 
survival duration after PDT treatment [Barber 2002]. Aside from tumour treatment, 
PDT has also been introduced to treat non-malignant diseases such as choroidal 
neovascularization [Renno 2001]. 
1. Brief history of Photodynamic Therapy and fundamentals of Photosensitization 
 10
1.2 Molecular mechanism of photosensitization 
1.2.1 Photosensitization 
Photosensitization or photosensitized reaction is defined as a process where a 
substance absorbs photons and transfers the energy to reactants. This substance is 
named a photosensitizer. 
There are several photosensitization mechanisms. Two major processes are named 
Type I and Type II [Foote 1991]. Additionally, a broad definition of photosensitization 
that includes a Type III was also taken into account [Laustriat 1986]. In Type I 
reaction, the excited triplet state photosensitizer (3P*) reacts with the substrate 
molecule (S) and forms radical pairs or radical ions, as shown in Eqs. 1.1 and 1.2. 
3 * +P S P S⋅− ⋅+ ⎯⎯→ +                                                             (1.1) 
3 *P S P S⋅+ ⋅−+ ⎯⎯→ + .                                                            (1.2) 
This resulting radical species of Type I reaction can participate in many different 
reactions. 
The main photosensitization involved in photodynamic therapy is Type II since most 
photosensitizers in triplet state transfer their energy to oxygen under normal 
physiological conditions [Dougherty 1998]. With oxygen participation, excited 
photosensitizer molecules transfer energy to molecular oxygen and cause singlet 
oxygen generation. Type II can be written as Eq. 1.3: 
3 * 1
2P O P g
⋅−+ ⎯⎯→ + ∆ .                                                       (1.3) 
The entire photochemical process of Type II photosensitization is shown in Fig. 1.1. 
1. Brief history of Photodynamic Therapy and fundamentals of Photosensitization 
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Fig. 1.1. Jablonski diagram of activation and deactivation processes in Type II reaction. S0: 
photosensitizer ground state; S1, S2: photosensitizer excitation state; 3 g
−Σ : ground state of 
molecular oxygen; 1 2O : singlet oxygen. IC: internal conversion; and ISC: intersystem 
crossing 
 
Photosensitization Type III also produces radicals similar to Type I. However, unlike 
Type I, Type III occurs in the absence of oxygen. The excited photosensitizer 
molecules in Type III directly interact with the substrate molecules. Radicals are 
produced via electron transfer from excited state photosensitizer molecules to 
substrate molecules, especially in the photoreaction center [Laustriat 1986]. 
 
1.2.2 Deactivation of singlet oxygen via radiative way 
Singlet oxygen deactivation via radiative way includes singlet oxygen 
phosphorescence, chemiluminescence, and luminescence from the second excited 
vibrational level of the first excited singlet state. Here, singlet oxygen 
phosphorescence at 1270 nm is discussed. 
The measurement of singlet oxygen phosphorescence at 1270 nm is an efficient 
method for detecting singlet oxygen. However, since the spin restriction forbids 
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singlet oxygen phosphorescence is usually extremely weak. 
Singlet oxygen lifetime depends highly on solvents, ranging from 3.1–4.4 µs [Egorov 
1989, Rodgers 1982] in water to approximately 1200 µs in C2Cl4 [Salokhiddinov 
1981]. The value of singlet oxygen lifetime is influenced by the infrared absorption of 
CH, CC, and OH groups near 1270 nm, where 1O2 transfers its electronic excitation 
energy to the vibrational energy level of solvent molecules. Aside from oxygen-
solvent energy transfer, the oxidation-reduction reactions in the solutions also 
influence singlet oxygen lifetime. For example, compared with singlet oxygen 
lifetime of 3.1–4.4 µs in water, the singlet oxygen lifetime in D2O induced by solvent 
isotope effect is approximately 60 µs. In theory, understanding the energy transfer 
process between singlet oxygen and solvent molecules is helpful to determine singlet 
oxygen quantum yield. On the practical side, it should be noted that photosensitizer 
molecules may be destroyed by extensive photobleaching in solvents where long 
singlet oxygen lifetime occurs [Ogilby 1983]. 
 
1.2.3 Singlet oxygen quantum yield 
The value of singlet oxygen quantum yield (Φ∆) is essential to evaluate potential 
photosensitizer molecules. Singlet oxygen quantum yield is defined as the ratio of 
photosensitizer molecules involved in singlet oxygen generation to total 
photosensitizer molecules in all triplet deactivation processes. 
The singlet oxygen quantum yield can be calculated using the equation given by 










∆ ∆ ∆Φ = Φ = Φ
+ +
,                         (1.4) 
where TΦ  is the triplet quantum yield; and SQ represents all deactivation processes, 
where oxygen is involved; S∆ is the percentage of SQ, which results in singlet oxygen 
generation; kO2 is the total rate constant; kp is the phosphorescence rate constant; and 
kelse is the rate constant of all non-radiative deactivation processes. 
Equation (1.4) can be also written as [Oelckers et al. 1997] 












Φ = Φ ,                                                        (1.5) 
where nearly every interaction of a tetrapyrrole molecule in the triplet state with 
oxygen results in singlet oxygen generation [Bensasson 1993]. Thus, S∆ is nearly 
equal or equal to 1. 
For the treatment of time-resolved singlet oxygen measurement data, Eq. (1.4) can be 










−Φ = ⋅ ,                                                    (1.6) 











+ − ,                                                                  (1.7) 
τ∆ is the singlet oxygen lifetime, and τΤair is the triplet state lifetime of the 
photosensitizer in oxygen-rich solution. The population of all photosensitizer 
molecules in triplet state is represented by nT(0). 
 
1.2.4 Singlet oxygen detection in cells 
Detection of singlet oxygen generation in living cells is the key to illustrate PDT 
molecular mechanisms on a cellular level, and will be helpful to novel 
photosensitizer-carrier system design. Singlet oxygen generation in cells can be 
indirectly detected, for instance, using laser flash photolysis [Paul 2003], or singlet 
oxygen quenchers such as beta-carotene [Trekli 2003], uric acid [Cavalcante 2009], or 
dichlorofluorescein diacetate [Tian, 2008]. 
Indirect singlet oxygen detection has an essential shortcoming in that it cannot 
distinguish the singlet oxygen intracellular localization because of the homogeneous 
singlet oxygen quencher distribution. Therefore, indirect singlet oxygen detection 
cannot offer detailed information regarding the interaction between singlet oxygen 
and cellular constituents. 
Singlet oxygen luminescence can be detected directly both with steady-state and time-
resolved methods. The steady-state method can provide an accurate determination of 
1. Brief history of Photodynamic Therapy and fundamentals of Photosensitization 
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the singlet oxygen quantum yield. However, it needs a high photosensitizer dose and 
long measurement period, which lead to photosensitizer photobleaching or cell death. 
These disadvantages prevent the steady-state method from being used in intracellular 
measurement. 
Although the time-resolved method requires a highly sensitive and rapid-response 
near-infrared photomultiplier and an elaborate design for signal collection and data 
processing equipment, it provides kinetic information of singlet oxygen generation 
and consumption. Furthermore, the singlet oxygen lifetime indicates its intracellular 
localization since this lifetime is decided by the distribution of singlet oxygen in 
micro heterogeneous environment. 
The most difficult problem of intracellular singlet oxygen luminescence detection is 
the short lifetime in H2O [Egorov 1989]. In previous studies, singlet oxygen 
luminescence was observed in D2O cell suspension [Gorman 1992, Baker 1992, Bilski 
1998]. D2O cell suspension has two shortcomings: cells behave abnormally in 
physiological measurements in D2O and, due to the solvent isotope effect, singlet 
lifetime in D2O/H2O cell suspension is difficult to estimate and unrepeatable [Skovsen 
2005]. More recently, the detection of singlet oxygen generated inside cells has been 
reported. In this case, the singlet oxygen lifetime is less than 0.5 µs due to effective 
quenching by proteins [Baier 2005, Snyder 2006]. 
If the photosensitizer is distributed in a microenvironment consisting of phospholipids, 
the singlet oxygen lifetime will be longer since the quenching rate constant of 
phospholipids is less than that of proteins [Baker 1992, Ehrenberg 1998]. However, 
singlet oxygen luminescence generating from phospholipids is too weak to be 
obtained. Due to the development of new detectors in the last few decades, it has 
become possible to observe tiny singlet oxygen luminescence generated from 
erythrocyte ghost membranes [Oelckers 1997]. Improved efforts have been reported 
in the last few years. For example, Baier et al. successfully obtained singlet oxygen 
luminescence from HT-29 cells [Baier 2005]. Singlet oxygen luminescence generated 
from subcellular structures has also been observed [Jiménez-Banzo, 2008; Hatz, 
2007]. However, the accurate determination of singlet oxygen lifetime is still hindered 
1. Brief history of Photodynamic Therapy and fundamentals of Photosensitization 
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by the small amount of singlet oxygen luminescence photons gathered from cells. 
Recently, Schlothauer et al. obtained accurate singlet oxygen lifetime data generated 
by pheophorbide a (Pheo) in Jurkat cells under low-dose irradiation using a highly 
sensitive detector built into a well-designed high signal-to-noise ratio setup 
[Schlothauer 2008]. 
Moreover, unlike other studies, this study handles singlet oxygen luminescence results 
combined with laser flash photolysis results. The benefit of combining laser flash 
photolysis and luminescence detection in the photobiophysik (PBP) group is that only 
the combined use of these two methods allows an explicit determination of singlet 
oxygen lifetime in cells. Singlet oxygen is generated via energy transfer from triplet 
state photosensitizer to molecular oxygen. This process must compete with all other 
triplet state photosensitizer deactivation processes. For this reason, the curve of time-
resolved singlet oxygen luminescence is determined by singlet oxygen decay and 
triplet decay together. Apart from other factors, singlet oxygen decay depends on 
oxygen and singlet oxygen quencher concentration. In contrast, the triplet lifetime 
usually maintains a nearly stable state. Thus, results will be more reliable when singlet 
oxygen data are analyzed combined with independent triplet lifetime measurement via 
laser flash photolysis [Hackbarth 2010]. 
The temporal shape of singlet oxygen luminescence in a homogeneous environment 
can be described using Eq. 1.8 [Oelckers 1999]. The obtained singlet oxygen 
luminescence decay curves are fitted with the two-exponential model function (Eq. 
1.8).  
( ) exp exp
air air
t tI t A τ
τ τ τ τ
∆
∆ ∆
⎡ − − ⎤⎛ ⎞ ⎛ ⎞= ⋅ − ⋅⎜ ⎟ ⎜ ⎟⎢ ⎥ −⎝ ⎠ ⎝ ⎠⎣ ⎦
.                              (1.8) 
The shape of singlet oxygen luminescence is determined by two competitive lifetimes: 
the triplet lifetime of photosensitizer, τT, and the singlet oxygen lifetime, τ∆. The 
rising of singlet oxygen luminescence is determined by the faster lifetime. The slower 
lifetime determines the signal decay. 
The photosensitizer triplet lifetime in solution is usually shorter than singlet oxygen 
lifetime. Therefore, the rising signal presents triplet lifetime, τT. The decay signal is 
1. Brief history of Photodynamic Therapy and fundamentals of Photosensitization 
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caused by singlet oxygen lifetime, τ∆. 
In contrast to singlet oxygen in solution, intracellular singlet oxygen can be quenched 
by endogenous chemical quenchers in cells. As a result, the singlet oxygen lifetime is 
usually shorter than the photosensitizer triplet lifetime. In this case, the rising signal is 
caused by singlet oxygen decay and the decay of the curve is determined by the triplet 
lifetime. 
In this Ph.D. thesis, further investigations that focus on the performance of singlet 
oxygen generated by photosensitizer-loaded nanoparticles in Jurkat and HT-29 cells 
are presented. With the aid of in vitro singlet oxygen results, the intracellular uptake 
mechanism, time-dependent photosensitizer distribution, nanoparticle decomposition, 
and photosensitizer release are analyzed (Chapters 4–8). 
 
1.3 Electronic excited states of molecular oxygen 
Ground state molecular oxygen, known as O2, plays an important role in the life cycle 
of organisms. The lowest occupation molecular orbital of ground state oxygen is 
(1σg)2(1σu)2(2σg)2(2σu)2(3σg)2(1πu)4(1πg)2. Many biochemical reactions need the 
participation of oxygen. The mechanism of oxygen-involved photochemical processes 
has been explained as early as the 1960s [Foote 1968]. Molecular oxygen in the 
ground state is non-reactive. However, some reactive oxygen species, such as singlet 
oxygen 1 g
+∆  and 1 g
+Σ , superoxide radical, hydroxyl radical, and peroxide radicals, are 
highly chemical active components. 
However, the lowest electronically excited state of oxygen, 
(2σg)2(2σu)2(3σg)2(1πu)4(1πg)4, has been studied in recent decades [Wilkinson 1993]. 
This active oxidant or “singlet oxygen” (1O2) has become the key to understand many 
types of photochemical reactions. 










Fig. 1.2. Occupation of molecular orbitals in oxygen: 
A. molecular oxygen; B. singlet oxygen    ; C. singlet oxygen     ; D. triplet state molecular 
oxygen T1; E. Superoxide radical; and F. peroxide ion [Hackbarth 2000] 
 
Ground state molecular oxygen, or      , has two unpaired p electrons. When excited, it 
can generate two singlet state species:     ,   with an energy of 94 kJ/mol, and 1 g
+Σ , 
with an energy of 157 kJ/mol higher than the ground state. The electronic transitions 
1 3
g g
+ −∆ ← Σ  and 1 3g g
+ −Σ ← Σ  are strictly spin forbidden. Thus, the efficiency of direct 
excitation with near-infrared light is very low. 
Singlet oxygen 1O2 can be generated by different activation pathways, such as the 
photosensitized generation by energy transfer from triplet state molecules via energy 
transfer exchanges. In the photosensitization process, the involved singlet oxygen 
species is 1O2. 
 
1.4 Requirements of an efficient photosensitizer 
PDT treatment efficiency depends on numerous factors, such as the choice of light 
source, light dose optimization, and delivery. However, a highly efficient 
photosensitizer with specific tumour targeting is always prioritized. 
An efficient photosensitizer should achieve the following requirements [Röder 2000]: 
1. Photophysical requirements 
It can be summarized from Fig. 1.1 that a potential candidate of photosensitizers 
should have a high intersystem-crossing quantum yield (ΦISC) and a high triplet 
quantum yield (ΦT). The triplet lifetime (τT) must also be long enough to induce 
singlet oxygen generation. The triplet state energy of photosensitizers must be very 
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requirements should be performed by a high singlet oxygen quantum yield (Φ∆). 
Aside from a high singlet oxygen quantum, a good photosensitizer should have strong 
absorption in the red or near-infrared region. The long wavelength for excitation is 
prioritized when choosing excitation sources since the penetration depth in most 
tissues increases with illumination wavelength. Tissues contain mainly water and 
protein. The most important protein chromophore in the visible region is the heme 
group (hemoglobin or Hb) and its oxidized derivative oxyhemoglobin (HbO2). Both 
Hb and HbO2 absorb light between 500 and 600 nm. However, their absorption 
decreases sharply at wavelengths longer than 630 nm. At this wavelength, light 
penetration depth is limited by hemoglobin and scattering [Wilson 1989]. At the same 
region up to 900 nm, water has only weak absorption. Thus, light usage in PDT 
treatment has maximum penetration in this region, known as the “cure window". The 
absorption of hemoglobin and water in the visible region is shown in Fig. 1.3. 
 
Fig. 1.3 Absorption spectra of hemoglobin (Hb), oxyhemoglobin (HbO2), and water, from 
[Wüstenberg 2006] 
 
2. Physicochemical/physiological requirements 
First, photosensitizer dark cytotoxicity should be very weak to avoid harm before 
PDT treatment. Next, the photosensitizer should be preferentially accumulated in the 
target tumour tissue, which offers the photosensitizer selectivity. Finally, after PDT 
treatment, the photosensitizer should be rapidly cleaned from the body. 
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A photosensitizer with these three characteristics minimizes PDT drug dose and drug 
residue inside the patient’s body. Unnecessary damage or side effects to surrounding 
healthy tissue can therefore be controlled within an acceptable level. 
Photosensitizer hydrophobicity is also reported to correlate to PDT efficiency [Pandey 
1996]. Hydrophobic photosensitizers are taken up and accumulated preferentially in a 
subcellular lipid environment. Conversely, these photosensitizers are water insoluble, 
which might induce a problem for photosensitizer delivery via plasma. One possible 
resolution to this contradiction is to couple hydrophobic photosensitizers with water-
soluble carriers such as serum proteins [Sternberg 1998], sugars [Ono 1992], 
dendrimers [Röder patent 2001], polymers [Hasan 1989], and nanoparticles 
[Allemann 1997, Moreno 2003, Yan 2003, Gu 2005, Wang 2004]. 
For decades, hematoporphyrin derivative (HpD) has been investigated and utilized as 
the first generation of photosensitizers. However, many problems still prevent it from 
being successfully used as a PDT treatment worldwide. HpD is derived from 
mammalian blood [Labbe and Nishida 1957]. The commercial hematoporphyrin, 
Photofrin®, is a mixture of monomers, dimers, and oligomers. Identifying and 
evaluating the PDT effective substance of this mixture are very difficult. Maintaining 
reproducibility when Photofrin® is produced commercially is challenging. The 
excitation wavelength for HpD is 630 nm, which is not sufficiently long to achieve 
deeper penetration in tumour tissues thicker than 4 mm. It takes 4–6 weeks for HpD to 
be cleaned from the body. During this long period, patients must stay in darkness to 
avoid side effects from unwanted phototoxicity [Prasad 2003]. 
To overcome the shortcomings of first-generation photosensitizers, second-generation 
photosensitizers, including modified porphyrins, chlorins, bacteriochlorins, and 
phorbides, were designed and synthesized as early as the 1980s [Dougherty 1998]. 
The family of porphyrins is a representative photosensitizer with an 18 π electron 
conjugated system. The absorption behaviour of porphyrins can be explained by 
Gouterman’s four orbital theory [Gouterman, 1961]. According to this theory, the 
absorption bands of metal-free porphyrins are caused by transitions among two 
highest occupied π orbitals, HOMO (au) and HOMO-1 (b1u), and two lowest 
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unoccupied π orbitals, LUMO (b2g) and LUMO+1 (b3g). The lower components of the 
Q bands are au→b3g and b1u→b2g transitions. The upper components of the Q bands 
are au→b2g and b1u→b3g transitions. The Q band absorption is relatively weak due to 
pseudoparity-forbidden state from alternancy symmetry [Hashimoto 1999]. The Soret 
band or B band consists of two transitions caused by the ground state to the second 
excited 21B3u and 21B2u states. The extinction coefficient at the Soret bands is strong 
since these transitions are highly allowed. Each of the two Q bands for free-base 
porphyrins splits into two vibrational bands. The position of the Soret bands is located 
in the blue region (c.a. 400 nm) and the Q bands between 500 and 700 nm. Although 
the absorption in Q band region is usually weaker than that in the Soret band, it is 
more important since longer excitation wavelength presents a benefit in PDT 
treatment, allowing for deeper penetration of the tumour tissue. 
A general character of second-generation photosensitizers is the red shift of the Q 
band absorption maximum by extending the macrocycle π-conjugation [Ehrenberg 
1990]. Stronger extinction coefficient at Qy (0, 0) band can be achieved by 
tetrapyrrole ring double bond reduction. A reduction of a pyrrole double bond on the 
porphyrin periphery generates chlorin, while an additional reduction of second pyrrole 
double bond generates bacteriochlorin because of the change in symmetry. Both types 
of components exist widely in nature and can be synthesized. They all have large Q 
band absorption at wavelengths λmax =650–670 nm for chlorin, and λmax =730–800 
nm for bacteriochlorin [Detty 2004]. 
In this Ph.D. thesis, the investigated photosensitizers are Pheo and mTHPP derivatives. 
Pheo is a decomposition product of chlorophyll a. It has been studied as a 
photosensitizer both in vitro and in vivo for a long period [Röder 1984, 1986, 1990]. 
It is a very efficient photosensitizer generating singlet oxygen both in its monomeric 
form [Röder 1984, 1990] or coupled with DAB-dendrimers [Hackbarth 2005]. Its 
derivative pyropheophorbide-a was proven phototoxic in vitro when conjugated to 
dendrimers and fullerenes [Paul 2003, Rancan 2005]. Unlike other derivatives of 
chlorophyll a, the series of pheophorbide derivatives are more attractive because of 
their in vivo activities. These activities originate from the alkyl ether chain [Pandey 
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1996]. Pheo has a strong absorption in the red region (668 nm) and causes high 
phototoxicity. It can also be extracted from leaves and spirulina in great amounts. For 
these reasons, Pheo is used as the starting compound for investigating the 
photosensitizer-nanoparticle carrier system (Chapter 4). 
5, 10, 15, 20-Tetrakis (3-hydroxyphenyl)-porphyrin (mTHPP) and its derivatives are 
developed as second-generation photosensitizers [Berenbaum 1986, Hagan 1988]. 
One of these derivatives, 5, 10, 15, 20-Tetrakis (3-hydroxyphenyl)-chlorin (mTHPC), 
was first recognized in 1946 [Ball 1946]. However, no further investigation was 
conducted due to synthesis difficulty. Whitlock developed a method using diimide to 
produce chlorins from porphyrins [Whitlock 1969]. However, the product is a mixture 
of porphyrin, chlorin, and bacteriochlorin, which presents a disadvantage. For this 
reason, mTHPC was not used as a PDT drug for a long time owing to purification 
difficulty. From the 1980’s, Berenbaum, Bonnett, and their co-workers began to 
investigate mTHPC PDT activity in vivo [Berenbaum 1989, Bonnett 1986]. As the 
corresponding dihydroporphyrin of mTHPP, the potential PDT drug mTHPC 
possesses many desired properties, such as strong absorption at 652 nm, non-
mutagenic quality, low dark toxicity, and stronger phototoxicity in vivo compared 
with mTHPP [Berenbaum 1993]. Commercially produced mTHPC (Foscan®) has 
already been approved by the European Medicines Evaluation Agency (EMEA) for 
the palliative treatment of advanced neck and head squamous cell carcinoma [Copper 
2003, Hopper 2004]. For these benefits, mTHPP derivatives, mainly mTHPC, are used 
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2. Tumour targeting and nanoparticle drug carrier system 
Most of current clinical antitumour drugs including photosensitizers are not 
selectively accumulated in cancer cells. Rapid elimination and widespread distribution 
of the drug in the patients’ body lead to high drug dose and thus unwanted side effects. 
These side effects include long term skin photosensitization for 4 to 6 weeks 
[Balchum 1985] and pain during PDT was characteristic for 1st generation 
photosensitizers. 
Selective drug delivery systems for tumour therapy have been studied for a long time. 
Detailed reviews to active and passive drug delivery systems were summarized by Jux 
and Röder [Jux and Röder 2009]. In general, two strategies can be utilized to increase 
the tumour selectivity of photosensitizer-loaded nanoparticles: the passive targeting of 
nanoparticles is designed according to the distinguishing physical properties between 
healthy tissues and tumour tissues; the active targeting can be achieved in active way 
by the attachment of a recognition unit to drug carriers such as e.g. special antibodies 
[Dressler 1992], peptides [Brokx 2002] and low-density lipoproteins (LDL) [Jori 
1993]. 
 
2.1 Passive strategies of tumour targeting 
Passive targeting strategies rely on the natural distribution pattern such as passive 
diffusion and phagocytosis processes to attain selective drug accumulation in target 
tumour tissue [Poste 1983]. The (enhanced permeability and retention) or EPR effect 
is the passive targeting mechanism that has been studied for a long time. It is to 
describe size-related drug accumulation in tumour tissue [Matsumura and Maeda 
1986]. The EPR effect bases on two facts: for one thing, disorganized angiogenic 
tumour vasculature with leaky endothelium leads hyperpermeability to circulate 
macromolecules and nanoparticles; for another, large molecule weight drugs in the 
interstitium can be retained due to lack of intratumoural lymphatic drainage. These 
properties of leaky vasculature give a priority to tumour tissues get more nutrients 
than normal tissues [Konan 2002a]. Therefore they play an essential role in rapid 
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growth of tumour. For this reason, large molecule weight drug with more than 40 kDa 
leads to significant tumour targeting (10-100 folds) in contrast to small molecule 













Fig. 2.1. In vivo transport and diffusion of small molecule weight drug and nanoparticle drug 
carrier system in healthy and tumour tissue and as well as in healthy and tumour vessel. After 
[Peer 2007] 
 
In recent research, many colloidal carriers were utilized for antitumour drugs to 
achieve EPR effect, for example, micelles [Van Nostrum 2004], liposomes [Derycke 
2004, Chen 2005], oil-based dispersions [Allemann 1997, Biolo 1996] and 
biodegradable nanoparticles [Konan 2003a, Stevens 2004] as well. 
 
2.2 Active strategies of tumour targeting 
Compared to passive strategy, the active strategy is more selective to tumour cells 
with special gene expressions. For instance, folinic acid-coupled poly ethylene glycol 
(PEG) nanoparticles have a ten-fold higher appearance in folate over expressed 
tumour cells than in normal cells [Stella et al., 2000]. It shows an increased uptake by 
K562 leukemia cells [Bellocq et al, 2003]. Antibody was also widely investigated to 
enhance intracellular uptake by tumour cells with over expressed receptors. 
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Trastuzumab for instance, was conjugated to HSA nanoparticles to target HER2 over 
expressing breast cancer cells [Anhorn 2008]. 
The benefits of passive tumour targeting strategy include ease-of-manufacturing and 
low-cost implementation. However, passive strategy has also deficits. It is less 
selective than active targeting strategy. Moreover, EPR effect is invalid if the size of 
tumour tissue is too small, which prevents its usage for early stage tumour or 
metastatic carcinoma. 
Active strategy is usually more direct and specific than passive strategy, especially in 
tumour cells with over-expressed receptors. However, the manufacture process is 
more difficult and the cost is more expensive. Furthermore, the conjugation efficiency 
and loading ratio of cell-specific agents are difficult to estimate. In case of 
nanoparticles, this problem is even more complex. 
 
2.3 Nanoparticle as drug carrier system 
Two problems prevent photosensitizer from further development. For one thing, no or 
low cell-specific selectivity of photosensitizer, which leads to side effects in health 
tissues; for another, the hydrophobicity of photosensitizer, which hampers intravenous 
administration. Therefore, suitable delivery drug systems become necessary to 
overcome the problems [Konan 2002a]. 
A good drug carrier should achieve requirements as follow: 
a. Well protection of the drug from degradation and leaky during pharmaceutical 
manufacture and clinical administration; 
b. Controllable drug release and enhanced drug targeting to tumour or other abnormal 
tissues; 
c. No or low toxic minimum to side effects; 
d. Suitable for different kinds of drugs. 
Nanoparticles can be defined as a colloidal particle system smaller than 1000 nm 
[Brigger 2002]. In the field of selective drug delivery, nanoparticles serve several 
roles: first of all, they can be used as carriers for drugs to achieve EPR effect [Wang 
2004]. The suitable particle size for PDT is in the range of 40 to 200 nm [Liu et al. 
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2002]. Nanoparticles show no or only a weak EPR effect when their size is less than 
40 nm. On the contrary, nanoparticles larger than 200 nm have an increasing 
possibility to be taken up by the mononuclear phagocytic system [Nagayasu et al., 
1999]. 
Besides EPR effect, the benefit of nanoparticles as PDT drug carrier system includes 
the improved biocompatibility [Konan 2002a] and high drug loading capacity as well 
as controlled drug release [Pramod 1990, Labib 1991, Kreuter 1983]. Many 
tetrapyrrole photosensitizers are hydrophobic. This character increases the affinity of 
photosensitizer for neoplastic tissues. But at the same time, the poor water solubility 
of hydrophobic photosensitizers in physiological media prevents the drug injection 
administration [Lin 1991, Pandey et al. 1996, Henderson et al. 1997]. After 
conjugated to water soluble nanoparticles, the bioavailability of PDT drug in vessel 
can be improved [Sinha 2006]. For active tumour targeting, cell-specific nanoparticles 
can be used as carrier for antibodies, DNA and other targeting units to enhance drug 
selectivity after surface modification. 
 
2.4 Biodegradable nanoparticles 
The hydrophobic photosensititizers are appropriate for intracellular accumulation. 
However, they are difficult to be administrated via injection. Organic biodegradable 
nanoparticles can promote intravenous administration of hydrophobic photosensitizers 
as well as their biodistribution [Jux and Röder 2009] 
In this PhD thesis, two types of biodegradable nanoparticles: human serum albumin 
(HSA) and poly (D, L lactide-co-glycolide) nanoparticles (PLGA) were used. Human 
serum albumin (HSA) is a common protein in blood plasma [Peters 1996, Carter 
1994]. HSA can interact with many kinds of organic and inorganic molecules [He 
1992, Peters 1985]. As a potential drug carrier, the benefits to use HSA nanoparticle 
include its biodegradability and non-antigenity [Rubino 1993]. The producing 
procedure of HSA nanoparticles is relatively easy and the size distribution can be 
controlled [MacAdam 1997]. Beside these, hydrophobic and hydrophilic drugs can be 
loaded to HSA nanoparticles via adsorption and covalent attachment [Weber 2000a]. 
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Surface modification is possible since the primary structure of HSA has been defined. 
The most convenience property of PLGA as drug delivery agent is its controllable 
degradation time and drug release kinetics. This can be achieved by adjusting the 
number and the ratio of lactide / glycolide [Lewis 1990]. The glycolide units are more 
hydrophilic than the lactide units [Cascone 2002]. So increasing glycolide unit ratio 
can lead to a quick drug release. On the contrary, higher lactide unit ratio strengthens 
the combination between hydrophilic drug and PLGA matrix. 
PLGA can be produced with quite easy methods, for instance, emulsion-evaporation 
[Gurny 1981] and emulsion-diffusion [Choi 2002, Niwa 1993]. PLGA nanoparticles 
can be used widely for drug delivery [Schachter 2002] and gene delivery [Panyam 
2003]. 
Similar to HSA nanoparticles, PLGA nanoparticles are also promising as drug carrier 
system for their biocompatibility and restorability [Lemoine 1996]. In general, the 
biodegradation rate of PLGA nanoparticles is proved to be faster than for other 
biodegradable polymer nanoparticles. However, this behaviour depends on the solvent 
and surfactant used during PLGA nanoparticles preparation [Jeong 2002]. Related to 
the size of PLGA nanoparticles, the drug release from the nanoparticles varies from 
several hours to couple of days [Allemann 1993, Landry 1997, Verracchia 1995]. 
Due to different preparation procedures, drug can only be loaded on the surface of 
HSA nanoparticles but incorporated into PLGA matrices. The intracellular 
nanoparticles decomposition and drug release of these two types of nanoparticles need 











3.1 Ground state absorption (UV-vis spectra) 
The ground state absorption spectra were recorded at room temperature using a 
commercial UV-vis Spectrometer UV-160 (Shimadzu). The measurement range of the 
absorption spectra is between 200 nm and 1100 nm. The absolute error at Optical 
Density (OD) =1 is 0.5% with reproducibility of 0.2%. 
 
3.2 Steady-state fluorescence 
The fluorescence spectra were taken at room temperature in optical quartz cells with 1 
cm optical path length using a Xenon lamp (XBO 150, OSRAM) with a 
monochromator (LOT-Oriel) for excitation and a polychromator with a cooled CCD 
matrix for detection (LOT-Oriel, Instaspec IV) [Regehly 2007]. The excitation range 
of the Xenon lamp is from 350 nm to 800 nm. The determination of the fluorescence 
quantum yield of sample requires a fluorescence standard reference. The fluorescence 










⋅                                                     (3.1) 
Here Φsam and Φref present the fluorescence quantum yields of sample and reference, 
respectively. εsam and εref refers to the extinctions of the sample and reference at 
excitation wavelength. Isam and Iref are the integrated fluorescence emission intensities 
of sample and reference. 
 
3.3 TCSPC 
3.3.1 Fluorescence lifetime measurements 
Time correlated single photon counting technique (TCSPC) was used to acquire 
fluorescence decay times. TCSPC technique is based on the detection of single photon 
of periodical light signal, the detection time measurement and the reconstruction of 
the measurement signal [O’Connor 1984, Becker 2005]. The TCSPC setup is shown 


















Fig. 3.1. TCSPC setup SHG: second harmonic generator; PD: photodiode; L1, 2, 3, 4, 5: lens; 
A: aperture; P1, 2: polarizer; S: sample holder; F: filter; MC: monochromator; MCP-PMT: 
micro-channel plate photomultiplier. 
 
The excitation light emitted from a Nd: VO4 laser (Cougar, Time Bandwidth Products) 
with a wavelength of 532 nm, pulse width 12 ps and a repetition rate of 60 MHz is 
separated into two beams: one is recorded by a photodiode and taken as a reference 
signal; the other beam is focused by lens and sent into sample chamber. The laser 
intensity is adjusted by tuning of the combination of polarizer P1 and P2. 
Optical density (OD) of the samples was 0.2 at the lowest energy absorption band. 
Fluorescence was detected under a polarization angle of 54.7° (magic angle) with a 
thermoelectrical cooled microchannel plate (R3809-01, Hamamatsu). Detection 
wavelength was chosen by a computer controlled monochromator (77200, LOT-Oriel). 
Electrical signals were processed by a PCI TCSPC controller card (SPC630, Becker & 
Hickl). 
Data were analyzed by a home made program using the least-square method and 
convoluted by the instrument response function (IRF) including a time shift. Detailed 
description of the TCSPC set-up is given in [Makarov 2006]. 
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The fluorescence intensity is an exponential function shown as follow: 
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Where instrument response function (IRF) is a time-depended function decided by the 
laser pulse and the response of photomultiplier. IRF can be measured with scattering 
material at excitation wavelength. 
The fitting quality is decided by χ2 in the least-square method. 
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Where Im(tk) is the measured data, If(tk) the fitting data. 
 
3.3.2 Decay associated fluorescence spectra (DAFS) 
Decay associated fluorescence spectra (DAFS) are global analysis applied to a 
multiple set of time-resolved fluorescence spectra [Davenport 1986, Willis 1990]. 
DAFS is the time-integrated fractional contribution to the total fluorescence spectrum. 
The calculation of DAFS is given with Equ. 3.4: 
1
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Where ( )i iα λ τ  is the fraction of fluorescence contributed by ith term fluorescence 
lifetime, Fluo(λ) the total steady-state fluorescence spectrum. 
 
3.4 Time-resolved singlet oxygen luminescence 
The intensity of singlet oxygen luminescence can be calculated using Eq. 3.5 
[Oelckers 1999]. 
( ) exp exp
air air
t tI t A τ
τ τ τ τ
∆
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                        (3.5) 
Where I is the intensity of singlet oxygen luminescence, A is a constant that depends 
on various instrument parameters and on the solvent. A is decided by the light 
excitation intensity, the photosensitizer absorption at excitation wavelength and the 
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photosensitizer concentration. A k∆∝ , k∆ is the singlet oxygen luminescence rate 
constant, which changes with the photosensitizer, and different other parameters like 
the quencher concentration, the oxygen concentration, the solvent. τ∆ is the singlet 
oxygen lifetime and τΤair is triplet state lifetime of the photosensitizer. 
The intensity of singlet oxygen luminescence changes in different solvents because 
the radiative lifetimes of singlet oxygen vary in different solvents [Gorman 1991].  
 
3.4.1 Singlet oxygen luminescence detection in solution 
Singlet oxygen luminescence at 1270 nm was detected with a liquid nitrogen-cooled 
Ge-diode detector Model EO-817P (North Coast, Inc., Santa Rosa, CA). All samples 
were excited with a Nd: YAG pumped OPO, NT 342/1 (Ekspla, Vilnius, Lithuania). 
The time-resolved singlet oxygen setup is shown in Fig. 3.2: 
 
Fig. 3.2. Experiment setup for time-resolved singlet oxygen luminescence measurement. 
 
The excitation light is attenuated by a gray filter and broadened by a collimator. A 
shatter controlled by computer served as time gate. Then excitation light is split by a 
beam splitter into two beams. One beam served as excitation to sample. The other is 
recorded by a powermeter. The detector signal is recorded by an oscilloscope [HP 
54542A, Hewlett Packard, USA] and then transmitted to computer [Oelckers 1997]. 
 
 














3.4.2 Singlet oxygen luminescence detection in living cells 
The singlet oxygen luminescence of photosensitizers located inside Jurkat cells was 
observed with the equipment described in [Schlothauer 2008]. This setup is exhibited 



































Fig. 3.3. Setup for singlet oxygen luminescence meaurements in cell suspensions, BS1, 2: 
beam splitter; M: mirror; L1, 2: lens; PD: photodiode; PM; powermeter; F: interference filter; 
MCP: multi-channel plate; AMP: pre-amplifier; TCMPC: home made TCMPC card.   
 
In this setup, a custom dye laser (DCM, 20 ns FWHM) is pumped by a frequency 
doubled Q-switching Nd: YAG laser (Serie 600, B.M. Industries). The power of beam 
is monitored by a powermeter (FieldMaster GS, COHERENT). The fluorescence and 
scattering light under 1270 nm are blocked by an interference filter (bk-1270-70-B, 
bk-interferenzoptik, Germany). The luminescence was focused on multi-channel plate 
photomultiplier (H-10330-45, HAMAMATSU) after gathered and collimated by 
optical system. The signal is sent to a computer equipped with a custom-made time-





3.5 Laser flash photolysis 
Laser flash photolysis (LFP) is a time-resolved “pump-probe” technique for studying 
the dynamics of triplet state photosensitizer. The earliest flash photolysis setup was 
developed by Norris and Porter [Norris 1924, Porter 1957]. The principle of “pump-





Fig. 3.4. Principle of “pump-probe” method. 
 
In the laser flash photolysis setup, an LED is taken as the probe pulse source. The 
short intense light pulse generated by a nanosecond pulsed laser Nd: YAG pumped 
OPO, NT 342/1 (Ekspla, Vilnius, Lithuania) is taken as excitation pulse. This intense 
light pulse excites ground state photosensitizer into excited singlet state. Then the 
photosensitizer molecules undergo inter-system crossing (ISC) to excited triplet state. 
This photo-induced absorption change is recorded by a Si-Diode with integrated fast 
pre-amplifier (Elektronik Manufaktur Mahlsdorf, Germany). The signal from Si-
Diode is digitalized with a fast digital oscilloscope (HP5415). The triplet decay time 
of photosensitizer can be calculated by analysing the transient absorption curve. The 
triplet decay time in air-saturated and in oxygen-depleted samples reflects the 
interaction between photosensitizer and oxygen. The laser flash photolysis setup is 




Fig. 3.5. Experimental setup for laser flash photolysis. 
 
According to Lambert-Beer’s law, the relation between transmission and absorption 
can be calculated by Eqs. 3.6 and 3.7: 
∆T = I / I0 = 10-εcL                                                                    (3.6) 
∆OD = log10 (1 / ∆T) = log10 (I0 / I)                                      (3.7) 
Where T is transmission, I is the intensity received by detector, ε is the molar 
extinction coefficient, c is the sample concentration, and L is the optical path length. 








Fig. 3.6. Change of transmission and absorption after laser pulse. 
 
When the change of transmission is not too much, the relation between transmission 
















3.6 Cell experiment 
The cell samples were prepared by Annegret Preuß and Carmen Ludwig. For in vitro 
experiments, Jurkat cells (clone E 6-1 human acute T-cell leukaemia) and HT-29 cells 
(Human colon adenocarcinoma grade II cell line) were cultured in RPMI 1640 
medium with L-glutamine (GIBCO) supplemented with 10% fetal calf serum (FCS), 
100 U/ml of penicillin and 100 lg/ml of streptomycin without phenol red [Rancan 
2005]. Cells were cultivated at 37 ºC in 100% humidity and 5% CO2 and were seeded 
in new medium every 2–3 days. 
Before intracellular singlet oxygen and triplet lifetime measurement, Jurkat cells 
(clone E 6-1 human acute T-cell leukaemia) and HT-29 cells were incubated in cell 
culture medium (RPMI 1640, GIBCO) with photosensitizer, following the procedure 
described in [Rancan 2005]. After incubation, the cells were harvested and counted 
(about 2×105 cells/ml). The cells were washed with PBS after centrifugation (room 

















4. Materials and basic experiments 
 35
4. Materials and basic experiments 
4.1 Photosensitizers 
Pheo is a dye first extracted from leaves of Urtica urens [Willstaetter 1913]. The Pheo 









Fig. 4.1. Structural formula of Pheo 
 
The photosensitizing molecules mTHPP and mTHPC were obtained from Biolitec AG 
and Prof. M. Senge (Trinity College, Dublin), respectively. 
 
Name Mol. Formula Mol. Weight 
Pheophorbide a C35H36N4O5 592.68 g mol-1 
mTHPP C44H30N4O4 678.75 g mol-1 
mTHPC C44H32N4O4 680.77 g mol-1 














                                   mTHPP                                                          mTHPC 
Fig. 4.2. Structural formula of mTHPP and mTHPC 
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The basic PDT-associated photophysical parameters of Pheo, mTHPP, and mTHPC 

















Pheo 406 60600 666 30000 673 0.22 0.52 
mTHPP 412 521600 645 9000 648 0.06 0.63 
mTHPC 417 207000 650 24000 652 0.07 0.65 
Table 4.2. PDT-associated photophysical properties of Pheo, mTHPP, and mTHPC; Solvent: 
ethanol; Fl λmax: Fluorescence maximum; Φfl: Fluorescence quantum yield; Φ∆: Singlet 
oxygen quantum yield 
 
As a phorbide, Pheo has a strong Q band absorption at the transition S0,0→ S1,0 with an 
extinction coefficient of ε=30 000 Mol-1cm-1 at 666 nm. More interestingly, the singlet 
oxygen quantum yield Φ∆ reaches 0.52 [Röder 1986]. 
The absorption spectrum of mTHPP has a typical character for porphyrin. The Soret 
band extinction coefficient is as high as 521600 Mol-1cm-1. At the same time, the 
transition S0,0→ S1,0 reduces to 9000 Mol-1cm-1, which becomes a shortcoming for PDT. 
The fluorescence quantum yield also has great attenuation compared to that of Pheo. 
The singlet oxygen quantum yield (0.63) is higher than that of Pheo. 
The mTHPC also has a very good ability to generate singlet oxygen. The singlet 
oxygen quantum yield in ethanol solution is 0.65. As a chlorin, it exhibits strong 
absorption at Qy (0, 0) band of S0,0→ S1,0 transition due to its degeneration of one side 
double bond in the porphyrin ring, which coincides with  the result of [Maillard 2007].  
 
4.2 HSA nanoparticles 
In preparing human serum albumin (HSA) nanoparticles, water-soluble 
glutaraldehyde was used to build cross-linkages between different HSA molecules. 
With glutaraldehyde, cross-linked solid HSA nanoparticles can be formed from 
unstable HSA colloids. HSA nanoparticles with more cross-linkages are usually more 
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stable during storage [Weber 2000a]. HSA nanoparticles with fewer amounts of cross-
linkages may decompose faster and release drugs more rapidly in cells. For this 
reason, the question of optimal cross-linkage is essential for development of new drug 
carrier systems. As will be demonstrated in this work, optimized cross-linkage can be 
















Fig. 4.3. Preparation of HSA nanoparticles, working group conference for BMBF-Project 
“Development of Cell Type Specific Drug Carrier Systems for Cancer Therapy 
(NanoCancer)”, June 2007 
 
One hundred percent (100%) and forty percent (40%) cross-linked HSA nanoparticles 
were obtained from Mathias Wacker, Institute of Pharmaceutical Technology, Goethe-
Universität, (Frankfurt, Germany). HSA-based nanoparticles prepared in the group of 
Prof. Klaus Langer [Langer et al. 2000] have a defined particle diameter between 100 
and 300 nm with a narrow size distribution [Langer et al. 2000, Weber et al. 2000a]. 
The fabrication process is shown in Fig. 4.3. 
 
4.3 PLGA nanoparticles 
Among numerous biodegradable polymers utilized in surgery and pharmaceutical 
industry, poly (lactic acid) (PLA) and poly (glycolic acid) (PGA) have been the most 
widely investigated. In recent decades, their copolymer, biodegradable poly (lactide-
co-glycolide) acid (PLGA), has also been considered to be a potential drug delivery 
agent [Birnbaum 2000] and gene carrier [Csaba 2005].  
The safety of both PLGA and its nanoparticles in vitro and in vivo has already been 
widely evaluated [Panyam 2003, Hirosue, 2001, Perez 2001]. In these studies, PLGA 
nanoparticles were proven to be taken up by certain kinds of cell lines, including 
dendritic cells. PLGA nanoparticles can be transported from endo-lysosomal 
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environment to cytoplasmic environment accompanied by drug release [Bivas-Benita 
2004]. 
 
Fig. 4.4. Preparation of photosensitizer-PLGA samples, T. Knobloch, “PLGA-nanoparticle as 
Carrier for Photosensitizer” working group conference for BMBF-Project “Development of 
Cell Type Specific Drug Carrier Systems for Cancer Therapy (NanoCancer)”, November 2007 
 
The PLGA nanoparticles studied in Chapter 5 are prepared via emulsion-diffusion-
evaporation method [Kwon, 2001]. mTHPP- and mTHPC-PLGA or poly (D, L 
lactide-co-glycolide) were provided by Thomas Knobloch, Institute of Pharmaceutics 
Technology, (Goethe-Universität, Frankfurt a. M.). 
 
4.4 Pheo-HSA nanoparticles as starting system 
The photophysical properties of Pheo-HSA nanoparticle-mixtures were investigated 
along with their in vitro photoactivity, as well as intracellular singlet oxygen 
luminescence. 
 
4.4.1 Preparation of Pheo-HSA nanoparticles 





Fig. 4.5. Preparation of photosensitizer-loaded HSA samples 
 
Pheo molecules were loaded on HSA nanoparticles by non-covalent drug adsorption. 
The molar loading ratio for Pheo and HSA was 4:1. PHSA40 are photoactive 
nanoparticles with Pheo adsorbed on the surface of 40% cross-linked HSA 
nanoparticles. PHSA100 are photoactive nanoparticles with Pheo adsorbed on the 
PLGA + PS + ethyl acetate 
PVA + water 
Ultrasonic homogenizing
17000 rpm, 10 min
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surface of 100% cross-linked HSA nanoparticles. 
Solutions of 100.0 µl Pheo-ethanol (1 mM) were added to 1.6 mg of 100% HSA 
nanoparticles (18.74 mg/ml in distilled water, or 0.288 mM) and 40% HSA 
nanoparticles (15.02 mg/ml in distilled water, or 0.231 mM), respectively. After Pheo 
addition, the mixtures were shaken with a minishaker (IKA-MS1, Milian AG) for 5 
min. The mixtures were then adjusted with distilled water to 2.0 ml by slow mixing at 
room temperature, and nanoparticles were suspended for 10 min by ultrasonication 
(Elma Hans Schmidbauer GmbH & Co. KG). Pheo-HSA nanoparticles showed an 
average diameter of 200 nm, as measured by photon correlation spectroscopy using 
laser light scattering with a Malvern zetasizer 3000HSA (Malvern Instruments Ltd., 
Malvern, UK) [Langer 2003]. The Pheo-HSA nanoparticles were proven to be stable 
for several days without changing photophysical properties. The absorption spectra, 
fluorescence spectra, and fluorescence lifetime of newly prepared Pheo-HSA 
maintained the same levels after a week’s storage. 
Unless otherwise stated, for all photophysical experiments Pheo was dissolved in 
ethanol (spectroscopic grade) and Pheo-HSA nanoparticles were dispersed in distilled 
water (MilliQ). 
 
4.4.2 Photophysical characterization of Pheo-HSA nanoparticles 
First, the absorption spectra were recorded to address the issue of nanoparticle 
influence on photosensitizer ground state properties. In particular, the problem of 
possible aggregation or ground state interaction with the nanoparticle had to be 
investigated because the absorption peaks will attenuate when photosensitizer 
molecules aggregate. Moreover, the positions of absorption peaks shift if interactions 
occur between photosensitizer molecules and nanoparticles. 
The absorption spectra of Pheo, PHSA40, and PHSA100 are shown in Fig. 4.6, and 
the data are given in Table 4.3. 
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Fig. 4.6. Absorption of Pheo, PHSA40, and PHSA100. Black line: Pheo; Red line: PHSA40; 
Blue line: PHSA100. Data are normalized at Soret band maximum (the scattering and 
absorption of HSA nanoparticles were taken into account). The Soret band and four Q bands 
locate from short wavelength to long wavelength, respectively. The most important Q band 
for PDT is Qy (0,0) band formed by S0,0→ S1,0 electron transition. 
 









Fl λmax [nm] Φfl (±1%) 
Pheo 406 60600 666 30000 673 1a 
PHSA40 400 24000 673 11000 678 0.14a 
PHSA100 402 26000 671 12100 677 0.14a 
a relative to Pheo 
Table 4.3. Photophysical parameters of Pheo, PHSA40, and PHSA100. Pheo was dissolved in 
ethanol; PHSA40 and PHSA100 were diluted in water. Since the fluorescence quantum yield 
is determined by comparison with a known reference, the error is mainly caused by the error 
of the reference, and thus it has the same percentage for all samples. (Fl λmax: Fluorescence 
maximum; Φfl: Fluorescence quantum yield.) 
 
As shown in Fig. 4.6 and Table 4.3, for all Pheo-HSA nanoparticles, the extinction 
coefficient of Pheo at S0,0→ S1,0 transition is reduced to approximately 1/3 compared 
with that of Pheo. The S0,0→ S1,0 transition is red-shifted to 673 nm for PHSA40 and 
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671 nm for PHSA100, compared with Pheo, where the S0, 0→ S1, 0 transition 
maximum is located at 666 nm. This shift is typical for Pheo if it is attached to large 
molecules such as dendrimers or nanoparticles [Hackbarth 2005]. At the same time, 
the full width at half maximum (FWHM) of the S0, 0→ S1, 0 transition of PHSA40 (39 
nm) and PHSA100 (45 nm) is broadened compared with that of Pheo (21 nm). These 
observations can be treated as a first hint for dye aggregation processes inside or on 
the surface of nanoparticles. 
The differing behaviours of Pheo and Pheo-HSA nanoparticles are more visible in 
steady-state fluorescence. The radiative transition from excited state Pheo to ground 
state will be weakened because of competition from all other non-radiative processes 
in the Pheo-HSA system. 
The steady-state fluorescence spectra of Pheo, PHSA40, and PHSA100 are shown in 
Fig. 4.7. 

























Fig. 4.7. Steady-state fluorescence of Pheo, PHSA40, and PHSA100.  Black line: Pheo; Red 
line: PHSA40; Blue line: PHSA100. Data are normalized at fluorescence peak. 
 
The bathochromic shift of Pheo attached to the nanoparticles was also observable in 
fluorescence. While Pheo shows its S1,0→ S0,0 transition peak at 673 nm, the 
fluorescence maximum of the PHSA40 is shifted to 678 nm, while PHSA100 is 
shifted to 677 nm. The relative fluorescence quantum yields for PHSA40 and 
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PHSA100 are approximately 14% of that of Pheo. The fluorescence bathochromic 
shift and the fluorescence intensity reduction of Pheo-HSA nanoparticles are probably 
caused by interactions between Pheo molecules. The attachment to the protein and the 
interaction with surrounding water molecules probably result in some strong 
interaction between closely neighboring Pheo molecules attached to one nanoparticle 
(Fig. 4.6, Table 4.3). 
To prove this theory, the excited Pheo singlet state lifetime was investigated using 
Time-Correlated Single Photon Counting (TCSPC). The results will reveal the pattern 
of fluorescence quantum yield attenuation in Pheo-HSA nanoparticles. 
Fluorescence lifetimes of Pheo and Pheo-HSA nanoparticles are listed in Table 4.4. 
 







Pheo 5.7/100 - - 1.02 
PHSA40 4.9/57.8 1.6/22.0 0.21/20.3 1.02 
PHSA100 5.0/53.1 1.8/23.7 0.29/23.2 0.97 
Table 4.4. Fluorescence lifetime of Pheo, PHSA40, and PHSA100 in solution. Pheo was 
dissolved in ethanol; PHSA40 and PHSA100 were diluted in water. Errors represent the 
standard deviation of data fitting. 
 
The fluorescence lifetime of Pheo in ethanol is 5.7 ns (Table 4.4). Three different 
lifetimes were observed for PHSA40 and PHSA100. The longest lifetime component, 
τ1,  approximately 5 ns, is only slightly shorter than that of Pheo. Such behaviour was 
also reported in case of other inhomogeneous Pheo molecules environments, such as 
in Pheo-dendrimer complexes [Hackbarth 2005] or coupled with antibodies [Röder 
2000b]. The second decay time, τ2, can be attributed to Pheo molecules undergoing 
different interactions that reduce normal fluorescence decay time. The shortest 
lifetime, τ3, is probably related to Pheo molecules having strong interactions. Pheo 
dimers or higher aggregates have little or no contribution to the PDT effect since their 
singlet oxygen quantum yield is negligible [Röder 2000b]. 
Pheo is a photosensitizer with high singlet oxygen quantum yield in solution. This is 
certainly favorable since good PDT therapeutic effect can be achieved even with 
minimal light and drug dose. However, the high singlet oxygen quantum yield will 
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also be a hazard if patients are unpredictably exposed to light. Therefore, 
photosensitizer-nanoparticle design should minimize the singlet oxygen quantum 
yield in solution. Low singlet oxygen quantum yield can be achieved in two ways: via 
low efficiency of energy transfer from triplet-state PS to molecular oxygen and via 
singlet oxygen quenching. Singlet oxygen luminescence determination and laser flash 
photolysis were investigated to study singlet oxygen generation of Pheo-HSA NPs in 
solution. 
The triplet lifetimes of Pheo, as well as PHSA40 and PHSA100 under normal air 
condition τTair and in oxygen-depleted samples τTN2, singlet oxygen lifetime τ∆, and 
singlet oxygen quantum yield Φ∆, are shown in Table 4.5. 
 
 τTair (µs) τTN2 (µs) fET τ∆ (µs) Φ∆  (±10%) 
Pheo a 0.16 ± 0.05 31 ± 3 0.99 15 ± 2  0.52 
PHSA40 b 7.9 ± 0.5 38 ± 4 0.79 11 ± 1 0.07 
PHSA100 b 6.4 ± 0.5 33 ± 3 0.81 11 ± 1 0.08 
Table 4.5. Triplet decay times of Pheo in ethanol, PHSA40, and PHSA100 in H2O air-
saturated τTair and flushed with nitrogen τTN2; Singlet oxygen lifetime τ∆ and quantum yield Φ∆; 
λexc: 673 nm; λobs: 488 nm. Pheo was measured in ethanol, Pheo-HSA nanoparticles were 
measured in D2O; Rose Bengal in D2O was taken as standard for Pheo-HSA nanoparticles 
 
The triplet lifetime τTair of Pheo in ethanol in air-saturated sample is quite short (0.16 
µs). However, the triplet lifetime in oxygen-depleted sample τTN2 is 31 µs, which 
makes the energy transfer efficiency factor fET = (τTN2 - τTair) / τTN2 nearly equal to 1. 
Pheo molecules in triplet state are rapidly quenched by molecular oxygen. This leads 
the large singlet oxygen quantum yield of Pheo (0.52) in ethanol. Triplet decay time 
τTair of PHSA40 and PHSA100 is 7.9 and 6.4 µs, respectively. The calculated fET of 
Pheo-HSA NPs decreases to 0.8, which demonstrates low energy transfer efficiency 
between Pheo and oxygen. 
The singlet oxygen quantum yield Φ∆ of Pheo molecules solved in ethanol is 0.52 
[Röder 1986]. For PHSA40 and PHSA100, values of 0.07 and 0.08 were obtained, 
respectively, which are in the region of the error margin. The singlet oxygen lifetime 
τ∆ for PHSA40 and PHSA100 is 11 µs. When compared with the value of singlet 
oxygen lifetime in D2O (60–70 µs), singlet oxygen generated by Pheo-HSA 
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nanoparticles is strongly quenched. There are two possible explanations for this 
phenomenon:  efficient interaction between Pheo molecules in the first excited singlet 
state, and Pheo aggregation on or near the nanoparticle surface. 
 
4.5 Photo-induced singlet oxygen generation in cells 
4.5.1 Laser flash photolysis 
In contrast to low singlet oxygen quantum yield in solution, the requirement for PS-
nanoparticle carrier system in targeting cells should be rapid drug release. The result 
of laser flash photolysis offers an indicator for intracellular drug release. Here, we use 
triplet lifetime as a tool to reveal this process in Jurkat cells. 
The singlet oxygen generation in Jurkat cells was studied indirectly using laser flash 
photolysis. The triplet decay time of Pheo was detected under air-saturated conditions 
and after flushing the sample for 40 min with nitrogen. The measurements were 
carried out for all photosensitizers after 24 h incubation. The measured triplet decay 
times (Table 4.6) indicate that Pheo molecules have already been released from HSA 
nanoparticles after 24 h incubation. This is evidenced in the similar triplet lifetimes of 
Pheo and Pheo-HSA NPs after 24 h incubation in Jurkat cells. Meanwhile, Pheo 
release was also proved by Annegret Preuß using confocal laser scanning microscopy 
(CLSM). 
 
 τTair (µs) τTN2 (µs) fET  
Pheo 1.8±0.3 35±7 0.95 
PHSA40 2.0±0.1 41±24 0.95 
PHSA100 2.1±0.1 68 ±34 0.97 
Table 4.6. Triplet decay times of Pheo, PHSA40, and PHSA100 in Jurkat cells air-saturated 
and flushed with nitrogen. Errors represent the standard deviation of three measurements. The 
error rates of τN2 are caused by low degassing efficiency. 
 
Indirect determination of singlet oxygen generation by laser flash photolysis reveals 
that Pheo and Pheo-HSA nanoparticles generate similar amounts of singlet oxygen in 
Jurkat cells after 24 h incubation. This experimental result is in agreement with the 
studies of phototoxicity done by Preuß [Chen et al. 2009]. The similar amount of 
singlet oxygen generated by Pheo and Pheo-HSA coincides with their high 
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phototoxicity in Jurkat cells after 24 h incubation. The singlet oxygen generation is 
also in good agreement with fluorescence lifetime imaging microscopy (FLIM) 
experiments conducted by Preuß [Chen et al. 2009]. The expected singlet oxygen 
generation inside cells and high phototoxicity were observed. 
Although the singlet oxygen quantum yields of PHSA40 and PHSA100 in solution are 
relatively low (Table 4.6), before Pheo releasing, the singlet oxygen generation of 
these samples was very low. This is in good agreement with the observed low 
phototoxicity of PHSA40 and PHSA100 after 1 h incubation [Chen et al. 2009]. When 
compared with the triplet lifetime τTair in solution (Table 4.5), triplet lifetime of Pheo 
and Pheo-HSA nanoparticles in cells after 5 h incubation reaches the same level. This 
indicates that Pheo molecules are discharged from HSA nanoparticles.  
 
4.5.2 Intracellular singlet oxygen luminescence 
To date, there is still one question that requires answering: Is Pheo released from HSA 
nanoparticles still capable of singlet oxygen generation? If yes, is this capability 
weakened? To reveal the answers, intracellular singlet oxygen luminescence 
measurement was conducted in two types of cell lines. 
The choice of incubation time is based on the intracellular uptake results obtained by 
Preuß [Chen et al. 2009]. The amount of Pheo inside Jurkat cells after 1 h and 3 h 
incubation is too small for quantified singlet oxygen luminescence detection. The 
intracellular uptake by HT-29 cells is even less than that of Jurkat cells. 
The choice of cell line is based on the comparable principle. The intracellular uptake 
and phototoxicity of Pheo and Pheo-HSA nanoparticles have been investigated by 
Preuß [Chen et al. 2009]. The relationship among intracellular uptake, phototoxicity, 
and intracellular singlet oxygen luminescence should be compared. However, Jurkat 
cells are not typical PDT target cells. As adenocarcinoma cells, HT-29 cells are ideal 
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 Jurkat cells 
 τ∆ [µs] ± 0.05 τTair [µs] Ι∆ a ± 30% 
Pheo 0.50 3.9 ± 0.2 100% 
PHSA40 0.70 3.7 ± 0.4 47% 
PHSA100 0.55 3.6 ± 0.5 29% 
 HT-29 cells 
Pheo 0.50 5.0 ± 0.5 100% 
PHSA40 0.50 3.8 ± 0.4 90% 
PHSA100 0.40 3.7 ± 0.4 117% 
Table 4.7. Singlet oxygen generation of Pheo and Pheo-HSA nanoparticles in HT-29 cells and 
Jurkat cells. Incubation time: 5 h; cell number: 5×105 cells/ml; illumination time: 20 s; λexc: 
668 nm; laser power: 1.5 mW. 
 
The results of intracellular singlet oxygen luminescence detection show that both 
Pheo and Pheo-HSA nanoparticles generate singlet oxygen in cells. The singlet 
oxygen lifetime in Jurkat cells is in the range of 0.40–0.70 µs, which is comparable to 
previous results [Schlothauer 2008]. The intensity of singlet oxygen luminescence 
generated by Pheo-HSA nanoparticles in Jurkat cells is less than that of Pheo. On the 
contrary, the singlet oxygen luminescence intensity of Pheo-HSA nanoparticles in HT-
29 cells is nearly the same as that of Pheo. This may indicate a faster Pheo release rate 
from HSA nanoparticles in HT-29 cells than in Jurkat cells after 5 h incubation. Even 
in Jurkat cells, however, Pheo discharge from HSA nanoparticles causes high 
phototoxicity after 24 h incubation, as shown by Annegret Preuß [Chen et al. 2009]. 
 
4.6 Conclusions 
The fluorescence quantum yield and fluorescence lifetime of PHSA40 and PHSA100 
in solution revealed interactions among the photosensitizer and HSA nanoparticles. 
For the same reason, the singlet oxygen quantum yield of PHSA40 and PHSA100 is 
significantly lower compared with that of Pheo. Due to the singlet oxygen quenching 
process caused by HSA nanoparticles, the singlet oxygen lifetime τ∆ of Pheo-HSA 
nanoparticles is shortened. Due to strong interactions, an extremely low singlet 
oxygen quantum yield Φ∆ of Pheo-HSA nanoparticles in solution is observed. 
Intracellular singlet oxygen luminescence further proves that Pheo-HSA nanoparticles 
can generate singlet oxygen because of Pheo discharge from HSA nanoparticles both 
in Jurkat and HT-29 cells after 5 h incubation. HSA nanoparticles are proven to be 
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useful in releasing photosensitizers in cells. Moreover, photosensitizers carried by 
HSA nanoparticles maintain singlet oxygen generation capability. 
Low dark toxicity and remarkable phototoxicity of the released dye molecules make 
Pheo-HSA nanoparticles potential candidates for PDT treatment. As the next step, 
other possible photosensitizers, such as mTHPP and mTHPC attached to the HSA and 
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5. HSA-nanoparticles as biodegradable carrier system for PDT 
In Chapter 4, the potential of HSA nanoparticles as photosensitizer carriers was 
demonstrated as they can transmit Pheo into Jurkat and HT-29 cells. After 24 h 
incubation, the singlet oxygen generation from Pheo-HSA inside both Jurkat and HT-
29 cells proves that Pheo molecules can be released from HSA nanoparticles. 
Pheo is a natural photosensitizer requiring extraction and purification from leaves or 
algae. Generally, the quality of mass production is difficult to control in the 
pharmaceutical industry. The synthetic photosensitizer mTHPP can be produced in 
large amounts with constant quality standards. Moreover, modification can be easily 
achieved by changing functional groups. For instance, chlorin mTHPC can be 
obtained by one-side double bond degeneration. Another functional group – hydroxyl 
group – promotes photosensitizer-nanoparticle conjugation. 
In this chapter, the ability of HSA nanoparticles to serve as carriers for mTHPP and 
mTHPC is investigated. The photophysical properties of mTHPP and mTHPC-HSA 
nanoparticles in dependence of loading ratio and degree of HSA cross-linking are also 
investigated. Furthermore, intracellular singlet oxygen generation by photosensitizer-
HSA nanoparticles in Jurkat cells is investigated to evaluate the photosensitizer 
release from HSA nanoparticles with different degrees of cross-linking. These results 
will be helpful to further optimize photosensitizer-loaded drug carrier systems since 
controlled drug release is one of the goals of a potential drug carrier. 
 
5.1 Photophysical properties of mTHPP-HSA with different loading ratios 
In the PS-loaded HSA nanoparticle preparation process, hydrophobic photosensitizer 
molecules are adsorbed on the surface of HSA nanoparticles. The surface area of HSA 
nanoparticles restrains maximum drug loading capacity. Within this range, whether or 
not the photophysical properties of low and high loading ratio mTHPP-HSA sample 
are maintained is an interesting question. This is discussed in the following section. 
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5.1.1 Sample description 
The mTHPP-HSA nanoparticles investigated here were prepared by Matthias Wacker, 
Institute of Pharmaceutics Technology, Goethe-Universität, Frankfurt, A. M., unless 
otherwise mentioned. mTHPP molecules were loaded on the surface of HSA 
nanoparticles using drug adsorption strategy. Dispersion media for mTHPP-HSA 
samples is water. 
mTHPP-HSA nanoparticles were loaded with different loading ratios. The high 
loading sample (HLPP-HSA) has a loading ratio of mTHPP/HSA 19.9 µg/mg or 
88.35% loading, while the low loading sample (LLPP-HSA) has a loading ratio of 
11.1 µg/mg or 49.31% loading. 
 
5.1.2 Absorption and steady-state fluorescence  
In Chapter 4, absorption spectra showed that the absorption of photosensitizer-loaded 
HSA nanoparticles is less than that of the free photosensitizer. However, it remains 
unclear whether or not the absorption changes once the drug-loading ratio increases. 
In this section, absorption spectra are taken when the loading ratio changes to study 
the influence of loading ratio on absorption. 
UV-vis absorption spectra of mTHPP and mTHPP-HSA were measured. The mTHPP 
was dissolved in ethanol, while mTHPP-HSA nanoparticles were diluted in distilled 
water. The concentration of mTHPP used in ethanol is 2 µg/ml or 3 µM. The 
concentrations of mTHPP contained in mTHPP-HSA samples were also adjusted to 3 
µM. 
The absorption spectra of mTHPP in ethanol and mTHPP-HSA nanoparticles in 
aqueous solution are shown in Fig. 5.1a. 
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Fig. 5.1a. UV-vis absorption spectra of mTHPP in ethanol and mTHPP-HSA in aqueous 
solution 
 
As can be seen from Fig. 5.1a, the absorption spectrum of free mTHPP consists of the 
Soret band transition and four Q band transitions with low absorption in the long 
wavelength region. The maximum of the mTHPP Soret band is located at 416 nm. The 
mTHPP-HSA Soret band has a bathochromic shift to 423 nm. The centers of four 
mTHPP Q bands in ethanol are 512, 546, 589, and 645 nm, respectively. Their 
counterparts for mTHPP in mTHPP-HSA nanoparticles are 517, 552, 591, and 648 nm. 
These red shifts in the absorption spectrum are caused by the photosensitizer attached 
to a large unit, such as the nanoparticle surface. 
To obtain real extinction coefficient from absorption of mTHPP in nanoparticles, the 
absorption data of mTHPP-HSA were scattering-corrected. Absorptions of mTHPP-
HSA are shown in Fig. 5.1b. 
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Fig. 5.1b. UV-vis absorption spectra of mTHPP in ethanol and mTHPP-HSA in aqueous 
solution after scattering calibration 
 
Both HLPP-HSA and LLPP-HSA show decreasing absorption in the Soret band 
region compared to mTHPP in ethanol. The relative intensity of the HLPP-HSA Soret 
band is 57% of that of free mTHPP in ethanol. At the same time, the relative intensity 
of the LLPP-HSA Soret band is 82% of that of free mTHPP in ethanol. This 
absorbance change relates to the photosensitizer-nanoparticle interaction formation 
due to the increasing concentration of HSA nanoparticles in LLPP-HSA sample. 
Similar behaviour of absorbance change in the case of photosensitizer-nanoparticle 
has been reported earlier [Wang 2005]. 
Absorption spectra show that high loading ratio sample has less absorbance, which 
also means less mTHPP molecules participate in fluorescence emission. As proof, the 
steady state fluorescence was excited at 411 nm. The fluorescence spectra of mTHPP 
in ethanol and mTHPP-HSA samples in aqueous solution are shown in Fig. 5.2. 
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Fig. 5.2. Steady-state fluorescence of mTHPP in ethanol and mTHPP-HSA in aqueous 
solution. Data were normalized 
 
The fluorescence curves of two mTHPP-HSA nanoparticles with different loading 
ratios are very similar in shape. The fluorescence peak of S1, 0→S0, 0 transitions for 
mTHPP-HSA nanoparticles has a bathochromic shift of 4 nm to 654 nm compared to 
that of mTHPP in ethanol. The fluorescence peak of S1, 0→S0, 1 transition of mTHPP-
HSA nanoparticles also shifts from 714 to 719 nm. This is typical behaviour when 
photosensitizers are coupled to a large unit, such as a dendrimer [Hackbarth 2005]. 
The ratio of S1,0→S0, 1 transition to S1, 0→S0, 0 transition in mTHPP-HSA 
nanoparticles decreases to 0.64 compared with 0.85 of mTHPP in ethanol. The 
fluorescence quantum yield of mTHPP-HSA nanoparticles is also reduced. Compared 
with mTHPP in ethanol, HLPP-HSA has 46% and LLPP-HSA has 57% of their 
fluorescence quantum yield. 
 
5.1.3 Fluorescence kinetic parameters 
High loading ratio HLPP-HSA has less fluorescence quantum yield than LLPP-HSA. 
There are two possible explanations: the population of mTHPP in excited state 
reduces, and the fluorescence of HLPP-HSA is strongly quenched. To resolve this, 
TCSPC is conducted to obtain fluorescence lifetime. 
Fluorescence lifetime measurements were carried out using TCSPC with the 
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following parameters: in Chapter 5, for all samples, the excitation wavelength 
λexc=532 nm, and fluorescence emission from mTHPP and mTHPP-HSA samples are 
recorded at 650 nm. 
Fluorescence lifetimes and their amplitudes of mTHPP-HSA in aqueous solution are 
shown in Table 5.1 
 
 τ1 [ns] ± 0.2 / 
A [%] 
τ2 [ns] ± 0.1  / 
A [%] 
τ3 [ns] ± 0.05 / 
A [%] 
τ4 [ns] ± 0.02 / 
A [%] 
χ2 
HLPP-HSA 8.7 / 19.3 1.3 / 8.4 - 0.019 / 72.3 1.06
LLPP-HSA 9.2 / 63.8 2.1 / 20.0 0.3 / 16.2 - 1.03
Table 5.1. Fluorescence lifetime of mTHPP in ethanol and mTHPP-HSA in aqueous solution 
 
The fluorescence spectra of mTHPP-HSA nanoparticles contain three fluorescence 
lifetime species for each sample. The shortened fluorescence lifetimes τ2, τ3, and τ4 
coincide with the reduced fluorescence quantum yields of mTHPP-HSA nanoparticles. 
The steady-state and time-resolved fluorescence data illustrate mTHPP-mTHPP 
interactions in mTHPP-HSA nanoparticles. However, these interactions change 
according to mTHPP loading ratio. The longest fluorescence decay component of 
mTHPP-HSA nanoparticles τ1 is caused by monomer-like mTHPP molecules similar 
to mTHPP (9.6 ns). However, this lifetime (8.7 ns for HLPP-HSA and 9.2 ns for 
LLPP-HSA) is shorter than that of free mTHPP, indicating that mTHPP monomer-like 
behaviour occurs when photosensitizer attached to large units, such as dendrimers 
[Hackbarth 2005]. The variables τ1 and τ2 can be obtained from the fluorescence 
decay of both samples. The main fluorescence component in LLPP-HSA is τ1 (63.8%). 
However, in HLPP-HSA τ1 only contributes 19.3% to the total fluorescence signal. 
Clearly, τ3 and τ4 distinguish HLPP-HSA and LLPP-HSA fluorescence decay. The 
fluorescence decay of LLPP-HSA contains τ3, which represents mTHPP-HSA 
interaction. In contrast, the shortest lifetime, τ4, exists only in the fluorescence decay 
of HLPP-HSA caused by strong mTHPP-mTHPP interactions. This result coincides 
with the fluorescence quantum yields of HLPP-HSA and LLPP-HSA. 
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5.1.4 Singlet oxygen generation 
Side effects of PDT such as skin photosensitization are caused by singlet oxygen 
generation outside tumour tissues or before treatment. The requirement to the third 
generation photosensitizer is to minimize singlet oxygen quantum yield outside 
targeting cells and to maximize singlet oxygen quantum yield inside targeting cells. In 
some cases, a photosensitizer with high singlet oxygen quantum yield generates little 
or no singlet oxygen when photosensitizers are combined with drug carriers. This 
phenomenon relies on a number of factors, such as the singlet oxygen quenching by 
drug carriers and the low efficiency between photosensitizer and oxygen. In the 
“NanoCancer” project, the manner in which singlet oxygen quantum yield during 
transportation is minimized depends on photosensitizer-nanoparticle attachment. 
Singlet oxygen generation of mTHPP in ethanol was also measured for comparison. 
mTHPP-HSA nanoparticles have weak singlet oxygen luminescence. Obtained singlet 
oxygen luminescence curves and fitting curves are shown in Fig. 5.3. 


























Fig. 5.3. Singlet oxygen luminescence of mTHPP-HSA nanoparticles in D2O. λexc: 514 nm; 
mTHPP Conc: 8 µM; Φ∆ standard for mTHPP-HSA NPs: Rose Bengal in D2O (Φ∆=0.75) 
 
According to the fitting data from singlet oxygen luminescence signal shown in Fig. 
5.3, singlet oxygen luminescence lifetime τ∆, triplet state lifetime of photosensitizer 
with and without oxygen τΤair and τΤN2, and singlet oxygen quantum yield Φ∆ of 
mTHPP-HSA can be calculated. Results are shown in Table 5.2. 
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 τΤair [µs] τTN2 [µs] fET τ∆ [µs] Φ∆ 
mTHPP 0.31 ± 0.05 47 ± 2 0.99 15.2 ± 0.5 0.63 ± 0.06a 
HLPP-HSA 29 ± 3 91 ± 3 0.53 42 ± 3 0.04 ± 0.03 
LLPP-HSA 33 ± 7 78 ± 2 0.41 29 ± 7 0.07 ± 0.03 
Table 5.2. Singlet oxygen generation and triplet decay of mTHPP in ethanol and mTHPP-
HSA in D2O. a: Φ∆ standard for mTHPP in ethanol: Pheo 
 
As can be seen from Fig. 5.3, for the same concentration of mTHPP loading on HSA 
nanoparticles, LLPP-HSA has higher singlet oxygen generation quantum yield. It 
achieves 11% of free mTHPP in ethanol. However, the singlet oxygen lifetime (29 µs) 
is much shorter than singlet oxygen lifetime generated by Rose Bengal in D2O (63–70 
µs). This indicates singlet oxygen quenching process in HSA nanoparticles since HSA 
is a highly effective singlet oxygen quencher [Korinek 2006]. The oxidation reaction 
constant of singlet oxygen to HSA was determined to be (5 ± 3) × 108 M-1S-1 [Davila 
1990]. During this process, singlet oxygen can be quenched by both the densely 
packed mTHPP molecules and the HSA around it. The different singlet oxygen 
generation behaviours of HLPP-HSA and LLPP-HSA can be explained by their 
loading ratios. In the case of LLPP-HSA, the percentage of photosensitizer monomers 
is higher, which can generate more singlet oxygen than a photosensitizer undergoing 
interaction. In contrast, the higher loading ratio of HLPP-HSA produces more energy 
traps or strong interactions among mTHPP molecules. Only a small amount of 
mTHPP molecules, which locate very closely to the surface between HSA 
nanoparticles and D2O, can generate singlet oxygen. In this way, HLPP-HSA singlet 
oxygen quantum yield is less than that of LLPP-HSA. Singlet oxygen generated by 
mTHPP in this case locates very closely to the HSA nanoparticle-D2O interface. 
Singlet oxygen lifetime τ∆ of HLPP-HSA (42 µs) is longer than that of LLPP-HSA 
(29 µs) due to its lower HSA concentration. 
Singlet oxygen generation can also be determined via laser flash photolysis. Triplet-
triplet photosensitizer absorption was investigated when comparing triplet decay 
behaviour in air-saturated and nitrogen-saturated solution. For laser flash photolysis 
measurement, mTHPP was dissolved in ethanol. mTHPP-HSA nanoparticles were 
diluted in D2O. The samples were excited with an ns-pulse laser pumped optical 
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parameter oscillator at 589 nm, and the change of absorption was monitored at 488 
nm. The samples were bubbled with nitrogen for 40 min at room temperature to 
remove oxygen in solution. 
mTHPP in ethanol exhibited a very short triplet decay time (0.31 µs) in the air-
saturated sample, indicating its high singlet oxygen generation efficiency. This also 
indicates that the difference of solvents should be considered. The mTHPP is in a 
hydrophobic environment and the concentration of oxygen in ethanol is different from 
that in D2O. Under normal air conditions, mTHPP-HSA nanoparticles exhibit a long 
triplet decay time (29 and 33 µs for HLPP-HSA and LLPP-HSA respectively). One 
possible reason could be that the mTHPP molecules are closely stacked on the HSA 
nanoparticles surface, which offers a lower oxygen concentration microenvironment. 
Another explanation could be the higher viscosity around the nanoparticles, which 
reduces oxygen diffusion rate [Aveline 1998]. 
 
5.2 Photophysical properties of mTHPC-HSA with different loading ratios 
In the last section, the loading ratio issue of mTHPP-HSA nanoparticles was discussed. 
The benefits of using mTHPP as photosensitizer include easy manufacture and 
relatively inexpensive production costs. It also can be conjugated to nanoparticles 
covalently. However, the low absorption in the Qy band region prevents mTHPP from 
further clinical PDT usage. In the “NanoCancer” project, mTHPC was chosen to be 
the final photosensitizer in following in vivo and clinical investigation. For this reason, 
more sophisticated photophysical study on mTHPC-HSA nanoparticles is 
demonstrated in the following section. 
 
5.2.1 Sample description 
mTHPC molecules were loaded on HSA nanoparticles (7.656 mg / ml) by non-
covalent adsorption. After mTHPC addition (1 mM), the mixtures were shaken with a 
minishaker (IKA-MS1, Milian AG) for 5 min and suspended for 10 min by 
ultrasonication (Elma Hans Schmidbauer GmbH & Co. KG). 
Samples in Section 5.2 contained different mTHPC/HSA loading ratios (Table 5.3). 
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For the preparation of HSA nanoparticles, glutaraldehyde was used as the cross-
linking agent. The amount of added glutaraldehyde mainly influences drug release 
and the stability of HSA nanoparticles during long-term storage [Weber 2000]. A 
typical amount of glutaraldehyde used for particle stabilization is between 40% and 
200% of the amount necessary for stoichiometric cross-linking of the 59 amino 
groups in the HSA molecule [Carter 1994]. The HSA nanoparticles used here have 
100% cross-linking, which means that theoretically, 100% of amino groups in HSA 
are cross-linked by glutaraldehyde. This loading procedure was carried by the 
candidate in PBP chemical laboratory. The dispersion media for all mTHPC-HSA 
samples is water. 
 
 CL Lr (µg / mg) 
NPL1 100% 4.5 
NPL2 100% 8.9 
NPL3 100% 17.8 
NPL4 100% 44.5 
NPL5 100% 89 
Table 5.3. Sample description: mTHPC-HSA nanoparticles with different loading ratios; CL: 
HSA cross-linking; Lr: Loading ratio mTHPC / HSA 
 
Unless otherwise mentioned, mTHPC was dissolved in ethanol for all photophysical 
investigations described in Sections 5.2 and 5.3. The mTHPC-HSA nanoparticles were 
diluted in distilled water. The concentration of mTHPC used in ethanol was 3 µM, 
while the concentration of mTHPC contained in mTHPC-HSA samples were also 
adjusted to 3 µM. 
 
5.2.2 Absorption spectra 
The most obvious effect in absorption is the dependency of both the strength and 
spectral position of the Soret band from the loading ratio (Fig. 5.4). 
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Fig. 5.4a. UV-vis absorption spectra of mTHPC in ethanol and water, and of mTHPC-HSA in 
aqueous solution, mTHPC Conc.: 3 µM (scattering corrected) 
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Fig. 5.4b. UV-vis absorption spectra (Soret band region) of mTHPC in ethanol and aqueous 
solution, and of mTHPC-HSA nanoparticles in aqueous solution, (scattering corrected) 
 




) FWHM (nm) 
mTHPC in ethanol 416.6  2.07×105 32.7  
NPL1 423.4  2.52×105 32.2  
NPL2 423.4  2.39×105 32.4  
NPL3 423.7  2.32×105 33.3  
NPL4 424.0  2.22×105 35.4  
NPL5 424.8  1.88×105 37.7  
mTHPC in H2O 427.2 1.49×105 54.2  
Table 5.4. Soret band maxima and extinction coefficient of mTHPC and mTHPC-HSA 
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The Soret band maximum of mTHPC in ethanol is at 416.6 nm and exhibits a large 
bathochromic shift, approximately 10 nm in aqueous solution. The Soret band 
maximum of mTHPC in NPL1 is at 423.4 nm and shifts slightly to 424.8 nm for 
mTHPC in NPL5. 
For mTHPC, the extinction coefficient at Soret band maximum decreases from 
2.07×105 M-1cm-1 in ethanol to 1.49×105 M-1cm-1 in water (Table 5.4). Accompanied 
by reducing extinction, the FWHM of the Soret band broadens to 54.2 nm compared 
to 32.7 nm of mTHPC in ethanol. 
For the loaded HSA nanoparticles, the extinction of the Soret band maximum 
continuously decreases from 2.52×105 M-1cm-1 for NPL1 to 1.88×105 M-1cm-1 for 
NPL5 (Fig. 5.4). The FWHM increases about 5.5 nm with increasing loading ratio. 



















mTHPC / HSA Loading ratio (µg / mg)
 
Fig. 5.5. Extinction coefficient in dependence on mTHPC / HSA loading ratio, mTHPC 
concentration: 3 µM 
 
As can be seen from Fig. 5.5, the extinction coefficient of the mTHPC correlates with 
the loading ratio. Moreover, the changes of the extinction coefficient are not linear 
with loading ratio increase. This observation suggests that, aside from the interaction 
of mTHPC molecules with the HSA nanoparticles, another type of interaction that 
occurs mainly at higher loading ratios should exist. Owing to geometric 
considerations, the interaction of mTHPC with the HSA nanoparticle should be nearly 
independent from the loading ratio. In contrast, at high loading ratio, the closer 
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positioning of the individual mTHPC molecules in each nanoparticle causing 
additional interactions between the dye molecules is highly probable. Owing to the 
superposition of these two effects, the extinction coefficient changes are not linearly 
dependent on the loading ratio. As a result, the intensity of this interaction does not 
simply depend on the number, but on the distance between neighboring molecules 
on/in the nanoparticle. At low loading ratio (< 10 µg/mg), more mTHPC molecules 
are “lone standing” or exhibit monomer-like behaviour. For these samples, the 
observed differences from mTHPC in solution are mainly caused by the interaction 
between the photosensitizer and HSA nanoparticles. 
At loading ratios between 10 and 40 µg/mg, the extinction coefficient is decreasing. 
This effect is even more pronounced at high loading ratios (> 44.5 µg/mg). For these 
samples, mTHPC-HSA interaction plays a minor role because of the influence from 
neighboring mTHPC. 
Since the interactions are visible in the ground state, it is highly probable that the 
mTHPC molecules undergo strong interactions. Such interactions have also been 
reported for other multichromophoric chlorin systems [Ermilov 2005, Hackbarth 
2005]. 
 
5.2.3 Steady-state fluorescence spectra 
























Fig. 5.6. Fluorescence spectra of mTHPC in ethanol and of mTHPC-HSA nanoparticles with 
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different loading ratios (mTHPC conc.: 3 µM; λexc: 506 nm) 
 
The fluorescence emission maximum of mTHPC in ethanol is at 653.8 nm (Fig. 5.6). 
The fluorescence peak of mTHPC-HSA nanoparticles in aqueous solution 
bathochromically shifts slightly. This bathochromic shift increases when drug loading 
ratio rises, and is accompanied by decreasing fluorescence emission. The fluorescence 
peak of NPL1 has a 2.5 nm bathochromic shift to 656.3 nm. This sample has 80% of 
fluorescence quantum yield compared to that of mTHPC. The fluorescence quantum 
yield of NPL3 is still 46.2%. However, the quantum yield decreases below 20% for 
NPL4. Furthermore, the fluorescence maximum of NPL5 shifts approximately 4.9 nm. 
It has only 8.6% of fluorescence quantum yield compared to that of mTHPC. The low 
fluorescence quantum yield and large red shift indicate that mTHPC-mTHPC 
interaction is dominant in high loading ratio samples. The fluorescence data are 
summarized in Table 5.5. 
 
Sample Lr [µg / mg] λmax[nm] 
of S1, 0→S0, 0
λmax [nm] 
of S1, 0→S0, 1
ΦFl [%] a 
NPL1 4.5  656.3 722.3 80.0 
NPL2 8.9  656.7 722.5 65.9 
NPL3 17.8  657.0 722.7 46.2 
NPL4 44.5  657.5 721.4 19.5 
NPL5 89  658.7 723.3 8.6 
Table 5.5. Fluorescence emission of mTHPC in ethanol and mTHPC-HSA in aqueous 
solution 
Lr: Loading ratio mTHPC/HSA; λmax:  Location of fluorescence maximum; ΦFL: Fluorescence 
quantum yield. 
a: Standard: mTHPC in ethanol. 
 
5.2.4 Fluorescence kinetic parameters 
Fluorescence lifetimes (τ) and their amplitudes of mTHPC in ethanol and mTHPC-
HSA nanoparticles in aqueous solutions are shown in Table 5.6. The fluorescence 
decay curves of mTHPC-HSA nanoparticles are shown in Fig. 5.7. 
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Fig. 5.7. Fluorescence decay curves of mTHPC and of mTHPC-HSA nanoparticles with 
different loading ratios 
 
Samples τ1 [ns] ± 0.2 / 
A [%] 
τ2 [ns] ± 0.1  
/ A [%] 
τ3 [ns] ± 0.1 / 
A [%] 
τ4 [ns] ± 0.05 / 
A [%] 
τ5 [ns] ± 0.02 / 
A [%] 
χ2 
mTHPC  8.5 / 100 - - - - 1.06
NPL1 8.5 / 51.3 3.5 / 26.8 - 0.37 / 21.9 - 1.1
NPL2 8.0 / 12.4 3.5 / 34.9 0.6 / 19.5 - 0.056 / 33.3 1.15
NPL3 - 3.4 / 6.4 1.3 / 21.0 0.35 / 25.6 0.040 / 46.9 1.08
NPL4 - - 1.0 / 6.8 0.29 / 27.7 0.040 / 65.5 1.14
NPL5 - - 0.8 / 3.3 0.20 / 15.8 0.027 / 80.9 1.12
Table 5.6. Fluorescence decay parameters of mTHPC in ethanol and of mTHPC-HSA 
nanoparticles with different loading ratios in aqueous solutions; λexc: 532 nm; λobs: 650 nm 
 
Fluorescence lifetime results coincide with fluorescence quantum yields. The 
fluorescence lifetime of mTHPC in ethanol is τ1=8.5 ns. The fluorescence lifetime of 
mTHPC in the HSA nanoparticles strongly depends on the drug loading ratio. 
Moreover, in difference to the dye in solution, multi-exponential decay behaviour was 
found. The lifetime τ1 (8.0 and 8.5 ns) is very similar to the fluorescence lifetime of 
mTHPC in ethanol and is therefore attributed to “lone standing” molecules in the 
nanoparticles behaving as monomers. The lifetime τ1 contributes more than 50% to 
the total fluorescence signal of NPL1. The percentage of τ1 decreases to 12.4% for 
NPL2. Interestingly, τ1 disappears in NPL3, which indicates that no more “lone 
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standing” mTHPC monomers contribute to emission. The fluorescence signal of 
NPL3 contains 6.4% of τ2 (3.3–3.5 ns), which could probably be attributed to 
mTHPC-HSA interaction. τ2 was observed for NPL1, NPL2, and NPL3. The 
contribution of τ2 is less than 0.1% when the mTHPC loading ratio is higher than 17.8 
µg/mg. The dominant parts in the fluorescence signal are three shorter fluorescence 
lifetimes (τ3, τ4, and τ5) when the loading ratio is higher than 44.5 µg/ mg. 
The disappearance of τ1 and τ2 in the fluorescence decay of NPL4 and NPL5 exhibits 
that the mTHPC-HSA interaction mechanism is negligible compared with mTHPC-
mTHPC interaction. Due to the strong dye-dye interactions, the fluorescence decay of 
high loading ratio samples NPL4 and NPL5 contains only three short lifetimes, τ3, τ4, 
and τ5. Thereby, τ3 (0.6–1.3 ns) and τ4 (0.19–0.37 ns) probably indicate different 
mTHPC-mTHPC traps, which means photosensitizers with excited state interaction 
cause a much faster decay time and much lower emission [Hackbarth 2005]. 
The contribution of the shortest lifetime τ5 caused by energy transfer to total 
fluorescence decay signal increases significantly from 33.3% for NPL2 to 80.9% for 
NPL5 (Table 5.6). The fluorescence quantum yield of mTHPC-HSA nanoparticles 
noticeably decreases from 65.9% for NPL2 to 8.6% for NPL5. This observation is 
typical for strong interacting molecules of random orientation. 
Low loading ratio samples exhibit stronger interaction between mTHPC and HSA 
(monomer mTHPC) as the interaction can be followed by absorption, steady-state 
fluorescence, and fluorescence lifetime analysis. In contrast, high loading ratio 
samples indicate stronger interaction between mTHPC molecules (traps, electronic 
energy transfer, etc.). 
 
5.2.5 Singlet oxygen generation and triplet lifetime in solution 
Singlet oxygen data and triplet lifetime of mTHPC in ethanol and of mTHPC-HSA 
nanoparticles measured in D2O are summarized in Table 5.7. Laser flash photolysis 
results are shown in Fig. 5.8. 
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Fig. 5.8a. Triplet decay curves of mTHPC-HSA nanoparticles in D2O under normal air 
conditions. λexc: 652 nm; λobs: 470 nm 























Fig. 5.8b. Triplet decay curves of mTHPC-HSA nanoparticles in D2O after 40 min N2 flushing. 
λexc: 652 nm; λobs: 470 nm 
 
Samples τTair [µs] τTN2 [µs] fET ∆OD a τ∆ [µs] Φ∆ (±0.02) b 
 NPL1 38 ± 3 106 ± 10 0.64 1 65 ± 5 0.04 
 NPL2 35 ± 3 103 ± 10 0.66 0.86 67 ± 5 0.03 
 NPL3 35 ± 3 98 ± 10 0.64 0.56 68 ± 5 < 0.03 
 NPL4 33 ± 3 104 ± 10 0.68 0.20 - - 
NPL5 41 ± 4 47 ± 4 0.13 0.14 - - 
Table 5.7. PDT-relevant photophysical parameters of mTHPC-HSA nanoparticles: triplet 
lifetime obtained under normal conditions: τTair, for air-depleted samples; τTN2, singlet oxygen 
lifetime (τ∆); and singlet oxygen quantum yield (Φ∆). 
a The change of absorption (∆OD) of NPL1 is taken as standard. 
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b All samples were excited at 652 nm in singlet oxygen measurement. TPPS in D2O is taken as 
singlet oxygen quantum yield standard (Φ∆ = 0.70). 
 
Owing to low absorption and strong scattering of mTHPC-HSA nanoparticles, 
determining the triplet quantum yield ΦT using picosecond-transient absorption 
spectroscopy (TAS) is difficult. However, the changing tendency of ΦT can be 
evaluated using ∆OD values obtained from laser flash photolysis experiments (Table 
5.7). The ∆OD indicates that ΦT decreases when the mTHPC loading ratio increases. 
The relative ∆OD decreases from 1 for NPL1 to 0.14 for NPL5, which means high 
loading ratio samples may have efficient triplet-triplet quenching (Fig. 5.8, Table 5.7). 
The low ΦT and fluorescence quantum yield ΦFL (Table 5.5) show that non-radiative 
intermolecular deactivation processes play the leading role in high loading ratio 
samples due to dye-dye interaction. 
The factor fET=(τTN2−τΤair) / τTN2 contains some information about singlet oxygen 
quantum yield Φ∆. The triplet lifetime τΤair under normal air condition is determined 
by τΤair= (kphor + knon-rad + kET[O2])-1 [Regehly 2007]. The triplet lifetime τTN2 after 
oxygen removal is given by τΤair= (kphor + knon-rad)-1. The triplet lifetime τΤair under 
normal air condition of mTHPC in ethanol was determined to be 0.23 µs, and τTN2 
after oxygen removal was 36 µs. Singlet oxygen quantum yields in ethanol and water 
are different due to the different oxygen concentrations. Therefore, the singlet oxygen 
generation of TPPS in D2O was measured as reference. The triplet lifetime τΤair under 
normal air condition of TPPS in D2O was determined to be 1.85 µs, and τTN2, after 
oxygen removal is 99 µs. The factor fET=(τTN2−τΤair) / τTN2 of TPPS in D2O and 
mTHPC in ethanol are in the range of 0.98–0.99, which indicates that 98%–99% 
triplet state photosensitizer molecules participate in singlet oxygen generation. This 
relates to their high singlet oxygen quantum yields (0.70 for TPPS in D2O and 0.63 
for mTHPC in ethanol). 
However, mTHPC-HSA nanoparticles in D2O have a long triplet lifetime τTair (33–41 
µs) under normal air condition (Table 5.7) compared to “free” photosensitizer TPPS in 
D2O (1.85 µs) and mTHPC in ethanol (0.23 µs). This long triplet lifetime indicates a 
change of oxygen diffusion rate within the microenvironment of mTHPC-HSA 
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nanoparticles. This may be caused by factors related to the preparation procedure of 
mTHPC-HSA nanoparticles since many factors can influence oxygen concentration, 
such as pH value, solvents, and the cross-linking structure of HSA nanoparticles. 
The τTN2 of oxygen-depleted mTHPC-HSA nanoparticles was determined to be in the 
range of 98–106 µs, except NPL5. The factor fET of all mTHPC-HSA nanoparticles, 
except for this sample, is in a narrow range of 0.64–0.68 (Table 5.7). For NPL5, the 
factor fET is 0.13. This factor coincides with its low singlet oxygen quantum yield 
(Table 5.7). 
In D2O, only NPL1, NPL2, and NPL3 are able to generate singlet oxygen with low 
quantum yield Φ∆ (Table 5.7). This is possible because some of mTHPC molecules 
behave like monomers. The singlet oxygen lifetime of mTHPC-HSA nanoparticles 
dissolved in D2O is in the range of 65–68 µs. This coincides with TPPS in D2O value 
of 64 µs. This means singlet oxygen generated from mTHPC diffuses out of the 
nanoparticles into D2O environment or it is generated on the surface of the 
nanoparticles. 
As can be seen from the photophysical characterization and singlet oxygen generation 
results, the choice of mTHPC loading ratio should be a compromise between loading 
efficiency and photophysical properties. HSA nanoparticles cannot be utilized 
efficiently when the loading ratio is lower than 17.8 µg/mg. However, no detectable 
singlet oxygen generation can be obtained for high loading ratios starting from 44.5 
µg/mg. For this reason, a fixed value in a narrow range of mTHPC loading ratio, 
approximately 17–20 µg/mg, was chosen for further investigation. 
 
5.3 Photophysical investigations of mTHPC-HSA with different cross-linkages 
HSA nanoparticles are connected by cross-linker glutaraldehyde. Aldehyde 
concentration ranges from 40% to 200% of the theoretic amount of the quantity 
necessary for connection to 59 amino groups in HSA. In a former work, the influence 
of cross-linker on particle size, zeta potential, and available surface amino group, as 
well as long-term storage, were studied [Lin et al. 1993, Roser 1993, Weber 2000]. In 
this section, the influence of the cross-linker of the HSA nanoparticles on 
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photophysical properties is investigated. This parameter is changed via different 
amounts of glutaraldehyde cross-linker added into the HSA molecules during 
preparation. 
The series of samples in this section were loaded at very similar ratios. Cross-linking 
of the HSA nanoparticles is presented in Table 5.8. 
 
 CL Lr (µg / mg)
NPC40 40% 19.05 
NPC100 100% 20.71 
NPC200 200% 20.59 
Table 5.8. Sample description: mTHPC-HSA nanoparticles with different cross-linkages 
CL: HSA cross-linking; Lr: Loading ratio mTHPC/HSA 
 
5.3.1 Absorption and steady-state fluorescence 
The amount of cross-linkers can change the number of available amino groups on the 
surface of HSA nanoparticles. The influence of changing cross-linkage on HSA NPs 
drug loading has been reported [Rubino 1993]. The final goal of the “NanoCancer” 
project is the stable and repeatable conjugation between photosensitizer and HSA 
nanoparticles. In this context, the photophysical properties, including absorption and 
steady-state fluorescence, were measured in order to investigate mTHPC-HSA NPs 
with different amounts of cross-linker. 



















Fig. 5.9. UV-vis absorption spectra of mTHPC in ethanol and of mTHPC-HSA nanoparticles 
with different cross-linkages in aqueous solution (scattering corrected) 
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The absorption spectra of the three mTHPC-HSA nanoparticle samples have similar 
shapes and extinction coefficient. The different degrees of cross-linking do not 
influence the absorption properties of the dye molecules. 























Fig. 5.10. Fluorescence spectra of mTHPC in ethanol and mTHPC-HSA nanoparticles with 
different cross-linkages in aqueous solution 
 
The maximum mTHPC-HSA nanoparticles fluorescence of the S1, 0→S0, 0 transitions 
locates at 657 nm, while the fluorescence peak of mTHPC is at 654 nm in ethanol. 
The fluorescence quantum yield of all three mTHPC-HSA nanoparticle samples is 
approximately 30% relative to mTHPC.  
 
5.3.2 Fluorescence kinetic parameters 
 
 τ1 [ns]  ± 0.1 /  
A [%] 
τ2 [ns] ± 0.1 / 
A [%] 
τ3 [ns] ± 0.05 / 
A [%] 
τ4 [ns] ± 0.010 /  
A [%] 
χ2 
NPC40 2.7 / 9.9 0.9 / 24.2 0.17 / 30.2 0.027 / 35.6 1.1 
NPC100 2.3 / 10.2 0.8 / 26.1 0.20 / 28.5 0.042 / 35.2 1.06
NPC200 2.1 / 10.3 0.7 / 30.6 0.21 / 25.6 0.045 / 33.5 1.07
Table 5.9. Fluorescence decay parameters of mTHPC-HSA nanoparticles with different cross-
linkages in aqueous solutions; A: amplitude; λexc: 532 nm; λobs: 650 nm 
 
The fluorescence decay of mTHPC-HSA nanoparticles consists of four fluorescence 
lifetime species (Table 5.9). However, three mTHPC-HSA nanoparticles have similar 
fluorescence decays. Monomer-like mTHPC molecules do not contribute to the 
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fluorescence of these mTHPC-HSA nanoparticles since τ1 is much shorter than the 
fluorescence lifetime of mTHPC in ethanol. 
The differences among absorption and fluorescence spectra of NPC40, NPC100, and 
NPC200 are negligible (Figs. 5.9 and 10). Both the fluorescence decay times and 
amplitudes of three mTHPC-HSA samples are quite similar (Table 5.9).  mTHPC-
HSA nanoparticles with different degrees of HSA cross-linking show no systematic 
differences in absorption, steady-state, and time-resolved fluorescence. This means 
that these parameters only depend on dye loading of the nanoparticles. They are 
independent of the density/rigidity of the HSA matrix. 
 
5.3.3 Singlet oxygen generation and laser flash photolysis 
Absorption and fluorescence spectra prove that different cross-linkers have no 
influence on photosensitizer molecules in the ground state and excited singlet states. 
In the next step, the work should move to characterization of the PS in triplet state as 
well as to its energy transfer to molecular oxygen. Singlet oxygen luminescence 
determination and laser flash photolysis are used to achieve this goal. 
Singlet oxygen and triplet lifetimes of the mTHPC-HSA nanoparticles are shown in 
Table 5.10. 
 
 τTair [µs] ± 3 a τ∆ [µs] ± 5 b Φ∆ (±0.02)
NPC40 30 67 0.04 
NPC100 36 66 0.03 
NPC200 42 55 0.03 
Table 5.10. PDT-relevant photophysical parameters of mTHPC-HSA nanoparticles with 
different cross-linkages in D2O; triplet lifetime under normal conditions; τTair, singlet oxygen 
lifetime (τ∆); and singlet oxygen quantum yield (Φ∆). 
aData obtained from laser flash photolysis. 
bAll samples were excited at 652 nm in singlet oxygen measurement. TPPS in D2O is taken as 
the singlet oxygen quantum yield standard (Φ∆ = 0.70). 
 
mTHPC-HSA nanoparticles have a long triplet lifetime τTair under normal air 
condition. This decay time increases with rising cross-linking of the HSA 
nanoparticles. τTair (42 µs) of NPC200 is slightly longer than the value of NPC40 (30 
µs) and NPC100 (36 µs) (Table 5.10). The longer triplet lifetime of NPC200 
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illustrates that stronger cross-linkage may induce less oxygen accessibility or 
diffusion within the dye microenvironment than in NPC40 and NPC100. 
The long singlet oxygen lifetime τ∆ of NPC40 (67 µs) and NPC100 (66 µs) (Table 
5.10) in D2O indicates that singlet oxygen diffuses out of the nanoparticles. For 
NPC40 and NPC100, singlet oxygen lifetime equals to the standard value in D2O (64–
70 µs). The shorter singlet oxygen lifetime τ∆ of NPC200 (55 µs) indicates weak 
singlet oxygen quenching. This effect could be caused by the tight inner structure of 
NPC200. HSA is an efficient singlet oxygen quencher [Davila 1990]. This suggests 
that the probability of singlet oxygen quenching during diffusion is higher because of 
more densely cross-linked HSA molecules in NPC200. 
Singlet oxygen quantum yield Φ∆ of the three mTHPC-HSA nanoparticles is low. 
Among them, Φ∆ of NPC40 (0.04) (Table 5.10) is slightly higher than the value of the 
other samples (0.03). This coincides with its shorter triplet lifetime τTair, which 
illustrates a looser HSA cross-linking structure with higher local oxygen concentration. 
However, this difference can be negligible. 
The photosensitized intracellular singlet oxygen luminescence in Jurkat cells 
incubated with mTHPC and NPC40, and NPC100 and NPC200 was investigated. 
 
5.3.4 Singlet oxygen luminescence detection in Jurkat cells 
Cross-linkage is considered an impact factor on biodegradability and drug release 
from the carrier system [Lee et al. 1981]. It is convenient if rapid and controllable 
drug release in targeting cells can be attained via adjusting glutaraldehyde cross-linker. 
Thus, in this section, the methods of singlet oxygen luminescence detection and laser 
flash photolysis are used in order to check the influence of cross-linker on drug 
release. 
Singlet oxygen generated from mTHPC is relatively independent of incubation time. 
It has only a slight reduction of singlet oxygen lifetime for 24 h incubation (Fig. 
5.11a). 
In the case of mTHPC-HSA nanoparticles, an increase of singlet oxygen lifetime τ∆ 
with incubation time of the cells can be clearly seen. After 1 h incubation, τ∆ of 
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mTHPC-HSA nanoparticles is in the range of 0.3–0.4 µs. This value gives an 
impression of mTHPC liberation from HSA nanoparticles [Preuß 2010]. With 
increasing incubation time, the singlet oxygen lifetime becomes longer. For NPC40 
and NPC100, τ∆ increases to the level of 0.55–0.6 µs after 24 h incubation. It is close 
to τ∆ of mTHPC (Fig. 5.11a). This can be explained by photosensitizer liberation from 
the nanoparticles. However, τ∆ of NPC200 (0.5 µs) still falls short compared to other 
samples after 24 h incubation. This finding suggests an incomplete release process of 
mTHPC from the nanoparticles, which coincides with the phototoxicity results [Preuß 
2010]. 



























Fig. 5.11a. Singlet oxygen lifetime in Jurkat cells incubated with mTHPC and mTHPC-HSA 
nanoparticles with different cross linkages. mTHPC Conc. 3 µM; illumination wavelength: 
652 nm; illumination time: 20 s; laser power: 1.5 mW; light dose: 1 µJ / cell 
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Fig. 5.11b. Triplet lifetime of the photosensitizer mTHPC in Jurkat cells incubated with 
mTHPC and mTHPC-HSA nanoparticles with different cross linkages 
 
Intracellular triplet lifetime also indicates mTHPC release from HSA nanoparticles. 
The triplet lifetime τTair of mTHPC in cells remains unchanged with a value of 3.7 µs 
for the different incubation times of 1, 3, and 5 h (Fig. 5.11b). After 24 h incubation, 
the triplet lifetime of mTHPC in Jurkat cells is 3.5 µs. The deviation is within the 
range of measurement error. In contrast, the triplet lifetimes of mTHPC-HSA 
nanoparticles show a decreasing tendency with increasing cell incubation time. The 
triplet lifetime of NPC200 after 1 h incubation is 4.4 µs. After 24 h incubation, it is 
decreased to 3.8 µs. τTair of NPC40 and NPC100 after 1 h incubation are 3.8 and 4.0 
µs, respectively. τTair of NPC40 and NPC100 is between 3.6 and 3.8 µs after 24 h 
incubation, which is longer than that of mTHPC but much shorter than that of 
NPC200. This result also illustrates drug release from HSA nanoparticles. However, 
τTair of NPC200 for all the times is slightly longer than other samples, which assumes 
an incomplete mTHPC release from NPC200. Controllable intracellular drug release 
can be achieved by adjusting the amount of glutaraldehyde. 
 
5.4 Conclusions 
Preparations for both mTHPP-HSA nanoparticles generate singlet oxygen 
luminescence in solution. Singlet oxygen quantum yield of LLPP-HSA (low loading 
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ratio sample) is higher than HLPP-HSA (high loading ratio sample). The singlet 
oxygen lifetime of mTHPP-HSA, however, is shorter than normal value (63–70 µs) in 
D2O. It seems that singlet oxygen quenching occurs in this photosensitizer-
nanoparticle system. 
The photophysical properties of mTHPC-HSA nanoparticles such as absorption and 
fluorescence spectra, as well as fluorescence lifetime, mainly depend on loading ratio. 
Low loading ratio samples exhibit stronger interaction between mTHPC and HSA 
(monomer mTHPC) as it can be followed by absorption, steady-state fluorescence, 
and fluorescence lifetime analysis. For low loading ratio samples (< 17.8 µg/mg), the 
leading mechanism is mTHPC-HSA interaction. The fluorescence lifetime and 
fluorescence quantum yield illustrate that low loading ratio mTHPC-HSA 
nanoparticles contain a fraction of mTHPC behaving like monomers. On the contrary, 
mTHPC-mTHPC interaction (traps, electronic energy transfer, etc.) becomes the prior 
interaction mechanism in high loading ratio samples (> 17.8 µg/mg). 
The choice of mTHPC loading ratio is a balance between photophysical properties 
and loading efficiency. A narrow range of loading (17–20 µg/mg) was determined 
when considering both properties. mTHPC-HSA nanoparticles with loading ratio in 
this range still have capability to generate singlet oxygen in a detectable amount.  At 
the same time, the loading ratio is sufficiently high for full utilization by HSA 
nanoparticles. For further investigation, the drug loading ratio for all of mTHPC-HSA 
nanoparticles was chosen from within this range. 
The cross-linkage influences photophysical properties that concern photosensitizer-
oxygen interaction such as the triplet lifetime τTair and singlet oxygen lifetime τ∆. 
NPC200 has the longest triplet lifetime. This means that the oxygen concentration 
within the microenvironment of mTHPC-HSA nanoparticles is strongly influenced by 
the amount of cross-linkages. Triplet lifetime τTair can be used as a realistic indicator 
for HSA NPs cross-linkage determination due to its high sensitivity and repeatability. 
In HSA nanoparticles with high number of cross-linkages, singlet oxygen can be 
quenched, resulting in shortened singlet oxygen lifetime. 
The singlet oxygen generation and triplet lifetime of Jurkat cells incubated with 
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mTHPC-HSA indicates that all samples generate singlet oxygen inside cells. After 24 
h incubation, the mTHPC molecules are released from the NPC40 and NPC100. In 
contrast, the high amount of cross-linkages makes NPC200 an unideal candidate as 
drug carrier since the required time for mTHPC release is too long. This can be 
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6. PLGA -nanoparticles as biodegradable carrier system for PDT 
In Chapter 5, photophysical properties of mTHPP- and mTHPC-HSA nanoparticles, as 
well as intracellular drug release and singlet oxygen generation, were discussed. As 
another interesting biodegradable nanoparticle, photosensitizer-combined PLGA 
nanoparticle was prepared [Konan 2002b] and evaluated in EMT-6 mammary tumor 
cells [Konan 2003b]. Photophysical characterization to photosensitizer-loaded PLGA 
NPs and the intracellular singlet oxygen generation are discussed in this chapter. In 
particular, the highlight will be the research of drug release from PLGA matrices in 
organic solvent, cell culture media, and inside cells by monitoring the triplet lifetime 
of photosensitizer. This is carried out using laser flash photolysis. 
 
6.1 Comparison of the photophysical properties of mTHPP- and mTHPC-PLGA 
mTHPP and mTHPC molecules were incorporated into the PLGA nanoparticles 
matrix. Dispersion medium of the mTHPP-and mTHPC-PLGA nanoparticles is 
distilled water. Concentrations of incorporated mTHPP and mTHPC are 0.720 and 
0.768 mg/ml, respectively. For mTHPP-PLGA nanoparticles, the loading ratio is 89.53 
µg mTHPP/mg PLGA. For mTHPC-PLGA nanoparticles, the loading ratio is 83.21 µg 
mTHPC/mg PLGA. 
 
6.2 Absorption and steady-state fluorescence 
To compare photophysical properties of mTHPP and mTHPC-PLGA NPs, absorption 
and steady-state fluorescence are taken as follows. 
UV-vis absorption spectra of mTHPP, mTHPC, mTHPP-, and mTHPC-PLGA were 
measured. If without special descriptions, mTHPP and mTHPC were dissolved in 
ethanol. mTHPP- and mTHPC-PLGA were diluted with distilled water. The 
absorption spectra of mTHPP, mTHPC, mTHPP-, and mTHPC-PLGA are shown in 
Fig. 6.1. 
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Fig. 6.1a. UV-vis absorption spectra of mTHPP, mTHPC in ethanol, and mTHPP- and 
mTHPC-PLGA nanoparticles in aqueous environment 


















Fig. 6.1b. UV-vis absorption spectra of mTHPP, mTHPC in ethanol, and mTHPP- and 
mTHPC-PLGA nanoparticles in aqueous environment, scattering corrected 
 
As shown in Fig. 6.1a, the maximum of the Soret band of mTHPP is located at 413 
nm. For mTHPP-PLGA, it is bathochromically shifted to 423 nm. The real extinction 
from absorption when scattering is considered is shown in Fig. 6.1b. The absorption at 
Q band region is drawn separately in Fig. 6.1c to get a better view of Q band region. 
The four Q band maxima of mTHPP-PLGA locate at 515, 550, 590, and 646 nm. At 
the same time, their mTHPP counterparts are at 512, 546, 588, and 645 nm. Although 
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Q band maxima of mTHPP-PLGA have also systematically red-shifted, the shift is not 
as significant as at the Soret band maximum. 
After scattering correction, the absorption of the mTHPC-PLGA is very similar to that 
of mTHPC in ethanol, except in the shift of absorption maxima. The Soret band 
maximum of the mTHPC-PLGA absorption spectrum locates at 425 nm, while the 
Soret band maximum of the absorption spectrum of mTHPC is at 416 nm. This shift is 
probably caused by the interaction of mTHPC with the PLGA matrix. The four Q 
band maxima in the absorption of mTHPC are located at 515, 541, 594, and 650 nm. 
Their counterparts in the absorption of mTHPC-PLGA shift to 520, 546, 597, and 652 
nm. 


















Fig. 6.1c. UV-vis absorption spectra of mTHPP, mTHPC in ethanol, and mTHPP- and 
mTHPC-PLGA in aqueous solution at Q band region 
 
Due to the degeneration of one double bond, the chlorin mTHPC has a stronger 
absorption in the Qx (0, 0) band than the porphyrin mTHPP. The extinction coefficient 
of mTHPC at 650 nm is approximately 24000 Mol-1cm-1, which is three fold higher 
than that of mTHPP (Fig. 6.1c). 650 nm is suitable for PDT. For this reason, mTHPC 
is regarded as a better photosensitizer than mTHPP [Berenbaum 1993]. 
The steady-state fluorescence of mTHPP and mTHPP-PLGA was excited at 414 nm. 
The steady-state fluorescence of mTHPC and mTHPC-PLGA was excited at 506 nm. 
Normalized fluorescence spectra of mTHPP, mTHPC, mTHPP-, and mTHPC-PLGA 
6. PLGA –nanoparticles as biodegradable carrier system for PDT 
 78
are shown in Fig. 6.2. 

























Fig. 6.2. Steady-state fluorescence of mTHPP, mTHPC in ethanol, and mTHPP- and mTHPC-
PLGA in water, data normalized 
 
Compared to mTHPP in ethanol, the relative fluorescence quantum yield of mTHPP-
PLGA is 0.38. Compared to 653 nm of mTHPC in ethanol, the fluorescence peak of 
the S1,0→S0,0 transition for mTHPC-PLGA nanoparticles is slightly shifted to 654.5 
nm. Compared to mTHPC, the relative fluorescence quantum yield of mTHPC-PLGA 
was calculated to be 0.07. The reduction of fluorescence quantum yield and 
appearance of different fluorescence decay times prove the occurrence of interactions 
between chromophores and PLGA matrix. 
To make full utilization of drug carriers, high drug loading ratio should be achieved. 
Nevertheless, prior evaluation of the influence of loading ratio on drug-loaded 
nanoparticles in vivo and clinical tests must be conducted. 
 
6.3 Fluorescence kinetic parameters and DAFS 
In Chapter 5, the influence of drug loading ratio on the photophysical properties of 
photosensitizer-loaded HSA nanoparticles, especially singlet oxygen generation, was 
shown. Fluorescence decay and singlet oxygen generation of mTHPP- and mTHPC-
PLGA nanoparticles with different loading ratios are studied in Sections 6.3 and 6.4, 
respectively. 
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mTHPP and mTHPC were encapsulated into PLGA matrices with different loading 
ratios. The dispersion medium of mTHPP- and mTHPC-PLGA is distilled water. The 
loading ratio of each sample is listed in Table 6.1. 
 
 PS Lr (µg / mg)
PNPL1 mTHPP 2.39  
PNPL2 mTHPP 10.07 
PNPL3 mTHPP 89.53 
CNPL1 mTHPC 1.72 
CNPL2 mTHPC 9.08 
CNPL3 mTHPC 83.21 
Table 6.1. Description of three mTHPP-PLGA and three mTHPC-PLGA nanoparticles. 
PS: photosensitizer; Lr: loading ratio PS / PLGA 
 
Fluorescence decay times and amplitudes of mTHPP and mTHPC in ethanol, and 
mTHPP- and mTHPC-PLGA in aqueous environment are shown in Table 6.2. The 
decay-associated fluorescence spectra of mTHPP- and mTHPC-PLGA are shown in 
Figs. 6.3 and 6.4, respectively. 
 
Samples τ1 [ns] ± 0.2 / 
A [%] 
τ2 [ns] ± 0.1 / 
A [%] 
τ3 [ns] ± 0.1 / 
A [%] 
τ4 [ns] ± 0.05 / 
A [%] 
τ5 [ns] ± 0.02 / 
A [%] 
χ2 
mTHPP 9.6 / 100 - - - - 1.06
PNPL1 11.7 / 66.7 4.0 / 14.1 - 0.58 / 19.2 - 1.07
PNPL2 8.2 / 23.5 - 1.6 / 23.4 - 0.21 / 53.1 1.01
PNPL3 8.7 / 7.4 - 1.5 / 33.2 - 0.26 / 59.4 1.19
mTHPC 8.5 / 100 - - - - 1.06
CNPL1 8.0 / 29.5 - - 0.75 / 26.0 0.15 / 44.5 1.18
CNPL2 - 3.9 / 10.6 1.1 / 29.5 - 0.22 / 60.0 1.13
CNPL3 - 2.8 / 0.3 - 0.52 / 7.8 0.14 / 91.9 1.27
Table 6.2. Fluorescence lifetime of mTHPP and mTHPC in ethanol, and mTHPP- and 
mTHPC-PLGA in aqueous solution. λexc: 532 nm; λobs: 717 nm 
 
Table 6.2 and Fig 6.3 show the fluorescence of each mTHPP-PLGA sample 
containing three different lifetimes. The fluorescence peaks of the S1, 0→S0, 0 
transitions for three different fluorescence components of mTHPP-PLGA 
nanoparticles are all located at 650 nm (Fig. 6.3). This indicates that the three decay 
times are generated by mTHPP. The amplitude of the longest lifetime τ1 (> 8 ns) 
decreases as the drug loading ratio rises. In low loading ratio sample PNPL1, the 
amplitude of τ1 is 66.7%. τ1 usually represents monomer-like mTHPP since the 
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fluorescence lifetime of mTHPP in ethanol (monomers) is 9.6 ns. In addition τ1, the 
fluorescence signal of PNPL1 also contains τ2 (4.0 ns, 14.1%) and τ4 (0.58 ns, 19.2%). 
These indicate that mTHPP molecules interact with PLGA matrices. In middle and 
high loading ratio samples PNPL2 and PNPL3, τ1 is reduced to 23.5% and 7.4%, 
respectively. These results indicate the reduction of mTHPP monomers in PLGA 
nanoparticles when the loading ratio increases. In these two samples, τ2 and τ4 are 
replaced by shorter lifetime τ3 (1.5–1.6 ns) and the shortest lifetime τ5 (0.21–0.26 ns). 
The shortened fluorescence lifetimes exhibit much closer mTHPP-PLGA interactions. 
It might be related to the localization of mTHPP in the PLGA matrix. One possible 
distribution of different fluorescence components could be that mTHPP clusters are 
trapped deeply inside the network of PLGA matrix while monomers locate mainly 
near the surface of nanoparticles. Nevertheless, more evidence is needed in order to 
prove fluorescence decay times. 







 τ1: 11.7 ns
 τ2: 4.0 ns














 τ1: 8.2 ns
 τ3: 1.6 ns






Wavelength (nm)  
                                 PNPL1                                                               PNPL2 






1,0  τ1: 8.7 ns
 τ3: 1.5 ns






Wavelength (nm)  
PNPL3 
Fig 6.3. Decay-associated fluorescence spectra of mTHPP-PLGA in water solution 
 
The fluorescence decay behaviour of mTHPC-PLGA nanoparticles differs from 
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mTHPP-PLGA nanoparticles. The fluorescence lifetime of mTHPC in ethanol 
(monomers) is 8.5 ns. Only CNPL1, the sample with the lowest loading ratio, contains 
monomer-like mTHPC (29.5%). For middle and high loading ratio samples CNPL2 
and CNPL3, there are no monomer-like mTHPC in the PLGA matrices. Even the 
lifetime τ2 (2.8–3.9 ns) of these samples contributes only 10% and 0.3% to the whole 
fluorescence signal. The very strong lifetime shortening speaks of efficient interaction 
processes. The main part of fluorescence signal of CNPL3 is contributed by the 
shortest lifetime τ5 (0.14 ns, 91.9%) (Table 6.2 and Fig. 6.4). These mTHPC-PLGA 
interactions are correlated with the loading ratio. This means they are correlated with 
increasing interactions between the dye molecules. The low fluorescence quantum 
yield and the shortened fluorescence decay time indicate that the dominant 
deactivation processes are non-radiative [Hackbarth 2005]. A similar behaviour was 
found for photosensitizer-loaded HSA nanoparticles. 







 τ1: 8.0 ns
 τ4: 0.75 ns














 τ2: 3.9 ns
 τ3: 1.1 ns






Wavelength (nm)  
                                 CNPL1                                                               CNPL2 






1,0  τ2: 2.8 ns
 τ4: 0.52 ns






Wavelength (nm)  
CNPL3 
Fig 6.4. Decay-associated fluorescence spectra of mTHPC-PLGA in water solution 
 
This result illustrates that mTHPC has a more pronounced tendency to aggregate in 
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PLGA nanoparticles than mTHPP. The different behaviour of mTHPP and mTHPC-
PLGA in fluorescence decay measurement should have a relation with the energy 
transfer efficiency between mTHPP and mTHPC dye molecules. The Förster radius of 
mTHPP and mTHPC in ethanol are 3.3 and 4.9 nm, respectively. The protonation of 
the imino nitrogen atoms will influence the electron distribution and change 
photosensitizer-photosensitizer interaction tendency. mTHPC reduces the protonation 
capability because of its degeneration [Cunderlikova 2001]. Therefore, 
hydrophobicity of mTHPC increases and thus leads to stronger aggregate tendency. 
 
6.4 Singlet oxygen generation and triplet lifetime 
Singlet oxygen quantum yield of PS-loaded HSA nanoparticles attenuates with 
increasing drug loading ratio (Chapter 5). PS-loaded PLGA NPs may not follow this 
pattern since PLGA NPs are produced by a different method. Photosensitizers are 
entrapped into matrices instead of surface-adsorbed. For this reason, whether or not 
the loading ratio determines singlet oxygen generation of PS-loaded PLGA NPs 
remains unknown. 
In this section, the singlet oxygen generation of mTHPP- and mTHPC-PLGA in D2O 
is measured. mTHPP- and mTHPC-PLGA nanoparticles have very weak singlet 
oxygen luminescence and shortened lifetimes, which leads to singlet oxygen 
quenching. Singlet oxygen generation and triplet lifetimes of mTHPP, mTHPC, 
mTHPP-, and mTHPC-PLGA in air-saturated solutions are shown in Table 6.3. 
 
 τTair [µs] τ∆1 [µs] τ∆2 [µs] Φ∆ [±0.03] 
PNPL1 31 ± 2 - 51 ± 3 0.10 
PNPL2 60 ± 1 - 43 ± 7 0.08 
PNPL3 9.5 ± 0.2 6.1 ± 0.5 [86%] 74 ± 6 [14%] 0.05 
CNPL1 29 ± 3 16.7 ± 0.3 - 0.12 
CNPL2 24 ± 8 12.7 ± 0.3 - 0.11 
CNPL3 22 ± 4 10.5 ± 0.2 - 0.08 
Table 6.3. Singlet oxygen lifetime τ∆, singlet oxygen quantum yield Φ∆, and triplet lifetime 
τTair of mTHPP-PLGA and mTHPC-PLGA. Singlet oxygen luminescence: λexc: 545 nm; 
Photosensitizer Conc.: 3 µM; OD: 0.1; Singlet oxygen quantum yield standard: Rose Bengal; 
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Solvent: D2O. Laser flash photolysis: λexc: 591 nm; λobs: 488 nm 
 
Typical singlet oxygen lifetime in D2O is 60 µs. However, the situations of mTHPP- 
and mTHPC-PLGA nanoparticles are quite complex. For mTHPP-PLGA, the singlet 
oxygen lifetime of the lowest loading ratio sample mTHPP-PLGA PNPL1 is 51 µs. 
This indicates that the singlet oxygen generated by PNPL1 is only slightly quenched 
before diffusion into the surrounding D2O. 
On the contrary, the singlet oxygen luminescence from high loading ratio sample 
PNPL3 is strongly quenched. The time-resolved singlet oxygen luminescence curve 
can be fitted with two exponential decays. The singlet oxygen lifetime of 6.1 µs (86%) 
is attributed to singlet oxygen, which undergoes quenching effect during diffusion. 
However, a small amount of singlet oxygen (14%) is diffused outside PLGA 
nanoparticles without quenching. One possible explanation is that they represent 
singlet oxygen generated from different locations. For instance, singlet oxygen with 
long lifetime generates near the PLGA nanoparticles surface, while singlet oxygen 
with shortened lifetime generates deeply inside the nanoparticles. 
Singlet oxygen generated from all three mTHPC-PLGA nanoparticles is quenched. 
The singlet oxygen lifetime generated from low loading ratio sample is 16.7 µs. The 
singlet oxygen lifetime decreases with increasing loading ratio, which indicates 
stronger singlet oxygen quenching process in high loading ratio samples. For this 
reason, the singlet oxygen quantum yield of all samples is low. Obviously, Φ∆ also 
decreases when the drug loading ratio increases. The observed decreased Φ∆  can 
partially explain the experimental fact observed by Zeisser et al., where increasing 
drug loading ratio reduces the phototoxicity of Hypericin-loaded PLGA nanoparticles 
on NuTu-19 cells [Zeisser-Labouebe 2006]. 
Photosensitizer-loaded PLGA nanoparticles have longer triplet lifetimes under normal 
air condition compared to Rose Bengal. This coincides with singlet oxygen 
measurement. Two possible reasons may cause long triplet lifetime: inefficient energy 
transfer between triplet state photosensitizer and oxygen; and lower local oxygen 
concentration within PLGA matrices than in D2O. 
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6.5 PLGA matrix decomposition in organic solvent 
Controllable decomposing and drug release in hydrophobic/hydrophilic environment 
are the goals of designing a drug carrier system. In this section, mTHPP- and mTHPC-
PLGA nanoparticles are dissolved in ethanol to investigate the PLGA degradation and 
drug release from PLGA nanoparticles. 
mTHPP and mTHPC in ethanol, and mTHPP- and mTHPC-PLGA nanoparticles in 
aqueous solution, were used for comparison. Absorption spectra of mTHPP, mTHPC, 
mTHPP-, and mTHPC-PLGA are shown in Fig. 6.5. 
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Fig. 6.5. UV-vis absorption spectra of mTHPP and mTHPC in ethanol, and of mTHPP- and 
mTHPC-PLGA in aqueous solution and in ethanol 
 
In comparison with mTHPP, the absorption maxima of mTHPP-PLGA demonstrated 
bathochromic shift compared to mTHPP, as mentioned in Section 6.2. However, 
mTHPP-PLGA dissolved in ethanol exhibited no band shift. At the same time, the 
scattering caused by PLGA nanoparticles in absorption of mTHPP-PLGA in water 
disappeared when the solvent was changed to ethanol. This illustrates that PLGA 
nanoparticles decompose to PLGA polymers when mTHPP-PLGA is dissolved in 
ethanol. mTHPP molecules trapped inside the PLGA matrix are released as monomers. 
This behaviour also exists in the absorption spectra of mTHPC-PLGA nanoparticles. 
The fluorescence quantum yield of mTHPP-PLGA in ethanol reaches 0.97 of the 
value of mTHPP. The relative fluorescence quantum yield of mTHPP-PLGA in 
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aqueous environment is only 0.38. The fluorescence quantum yield of mTHPP-PLGA 
in ethanol also reaches 0.94. These two findings indicate that PLGA nanoparticles do 
not quench fluorescence when they are dissolved in ethanol. 
In addition to steady-state fluorescence, fluorescence decay also illustrates whether or 
not drugs attach to nanoparticles. Fluorescence decay times and amplitude of all the 
samples are shown in Table 6.4. 
 
 τ1 [ns] ± 0.2 / 
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0.19 / 49.2 
 
0.089 / 46.7 
 
1.21
Table 6.4. Fluorescence lifetime of photosensitizer and photosensitizer-loaded PLGA 
nanoparticles in ethanol and in aqueous solution. λexc: 532 nm; λobs: 717 nm 
 
The fluorescence decay of mTHPP-PLGA nanoparticles in aqueous solution does not 
contain τ1. In aqueous solution, mTHPP molecules are trapped inside the PLGA 
matrix. The fluorescence lifetime of these mTHPP molecules shortens due to different 
interactions, probably dye-PLGA interaction or dye-dye interaction. As can be seen 
from Table 6.4, mTHPP-PLGA in ethanol exhibits similar fluorescence decay (9.6 ns) 
as mTHPP in ethanol (9.7 ns). These fall within typical fluorescence lifetime for 
mTHPP monomers. The fluorescence lifetime of mTHPP-PLGA in ethanol illustrates 
that mTHPP molecules are released from PLGA nanoparticles. 
The fluorescence lifetime of mTHPC-PLGA nanoparticles in ethanol is also similar to 
that of mTHPC. The longest lifetime, τ1, contributes to more than 90% of total 
fluorescence. 
In D2O, only very weak singlet oxygen luminescence generated from photosensitizer-
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loaded PLGA was observed. The singlet oxygen quantum yields of both mTHPP- and 
mTHPC-PLGA nanoparticles are very low (Table 6.3). The low singlet oxygen 
quantum yields as well as shortened singlet oxygen lifetimes of photosensitizer-
loaded PLGA nanoparticles in D2O are only caused by strong photosensitizer-
photosensitizer interactions inside PLGA matrices. However, both mTHPP- and 
mTHPC-PLGA nanoparticles generate singlet oxygen in ethanol (87% compared to 
mTHPP and 89% compared to mTHPC). The singlet oxygen luminescence curve and 
exponential fitting are shown in Fig. 6.6. 



























Fig. 6.6. Singlet oxygen luminescence of mTHPP, mTHPP-PLGA, mTHPC, and mTHPC-
PLGA in ethanol. λexc: 512 nm for mTHPP; λexc: 545 nm for mTHPC; Photosensitizer Conc. 
10 µM 
 
PLGA matrices are formed via emulsion-diffusion-evaporation method. They 
decompose and release trapped photosensitizers when PLGA nanoparticles are 
dissolved in ethanol. Photosensitizers released from PLGA matrices still generate 
singlet oxygen. However, a question needs to be answered: whether or not PLGA 
matrices release photosensitizers in cell culture medium and finally in cells. The 
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6.6 PLGA matrix decomposition and drug release in Jurkat cells 
Photosensitizer-loaded PLGA nanoparticles are characterized by their long triplet 
lifetimes. On the contrary, free photosensitizer in ethanol and in water has short triplet 
lifetime. Triplet lifetime of photosensitizer-loaded PLGA nanoparticles in aerobic 
environment is used as an indicator for PLGA decomposition and drug release since 
this method is fast and the result is credible. 
Baier et al. [Baier et al. 2005] reported that the decay time of singlet oxygen 
luminescence curve in HT-29 cells changes with incubation time, and identified the 
decay time as singlet oxygen lifetime. This has caused difficulty in explaining their 
result. In fact, the rise and decay of singlet oxygen luminescence are decided by the 
competition of two processes: triplet state photosensitizer decay and singlet oxygen 
decay. The decay time of singlet oxygen luminescence will be determined by the 
slower process [Hackbarth 2010]. The rising time of the curve is decided by the faster 
process. Both times can either be singlet oxygen lifetime or triplet lifetime. 
Data fitting singlet oxygen luminescence curves of mTHPP-PLGA nanoparticles 
incubated with Jurkat cells results in two decay times: the shorter time between 0.5 
and 1.0 µs is now considered as singlet oxygen lifetime. It coincides with the singlet 
oxygen lifetime of photosensitizer in cells [Hackbarth 2010]. The longer time is 
recognized as triplet lifetime. This lifetime changes dramatically with the incubation 
time. For this reason, this parameter was measured by determination of triplet-triplet 
absorption using laser flash photolysis in order to investigate behaviours of 
photosensitizer-loaded PLGA nanoparticles in different environments, including 
liposomes, protein solution, cell culture medium, and inside Jurkat cells. Triplet 
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Samples τTair1 [µs] Amplitude
% 
τTair2 [µs] Amplitude 
% 
mTHPP in ethanol 0.31 ± 0.05 100 - - 
mTHPP in 10% FCS solution 7.3 ± 0.4 100 - - 
mTHPP in RPMI 9.2 ± 0.3 100 - - 
mTHPP in liposomes 1.8 ± 0.2  100 - - 
mTHPP in cells 5 h 3.0 ± 0.2 100 - - 
mTHPP-PLGA in H2O - - 70 ± 4 100 
mTHPP-PLGA in RPMI 7.9 ± 0.6 41.9 86 ± 5 58.1 
mTHPP-PLGA in cells 1 h - - 18 ± 3 100 
mTHPP-PLGA in cells 3 h 3.4 ± 0.3 100 - - 
mTHPP-PLGA in cells 5 h 3.2 ± 0.2 100 - - 
mTHPP-PLGA in cells 24 h 2.7 ± 0.2 100 - - 
Table 6.5. Triplet lifetimes of mTHPP and mTHPP-PLGA in different environments under 
normal air condition. RPMI 1640: cell culture media with FCS 10%; Liposome: DPPC; Cell 
line: Jurkat cells; λobs: 470 nm; λexc: 515 nm 
 
Hydrophobic mTHPP in ethanol under normal air conditions inhibits a very short 
triplet lifetime (0.31 µs), which indicates highly efficient energy transfer between 
triplet state photosensitizer and ground state oxygen. 
mTHPP molecules form aggregates in hydrophilic solution. For this reason, triplet 
lifetime of mTHPP in water cannot be detected. However, τTair of mTHPP in cell 
culture medium RPMI 1640 containing protein Fetal Calf Serum (FCS) and in 10% 
FCS water solution were obtained (7.3 and 9.2 µs, respectively). These two times 
could be observed because mTHPP molecules are attracted by the plasma proteins. 
Such photosensitizer-FCS combination behaviour has been reported by Hadjur 
[Hadjur 1998]. 
Bi-layer liposomes composed of phospholipids offer an environment in which mTHPP 
behaves similarly as in cell membranes [Lasic 1997]. The triplet lifetime of mTHPP in 
liposomes prepared using Dipalmitoylphosphatidylcholine (DPPC) was investigated. 
In this case, triplet lifetime was determined to be 1.8 µs. This is longer than τTair in 
ethanol, but shorter than the τTair of mTHPP combined with plasma protein. 
The long triplet lifetime (70 µs) of mTHPP-PLGA in air-saturated aqueous solution 
indicates the low intersystem crossing quantum yield. For photosensitizer molecules 
encapsulated within PLGA matrices, many non-radiative deactivation processes 
compete with intersystem crossing. This relates to low singlet oxygen quantum yield 
of mTHPP-PLGA nanoparticles. 
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The triplet decay of mTHPP-PLGA in protein-containing RPMI medium contains two 
components that relate to two populations of mTHPP molecules with different 
localizations. One is 7.9 µs, or short triplet lifetime, which is similar to τTair of mTHPP 
in FCS-containing RPMI. This lifetime is caused by mTHPP combined with FCS. The 
second lifetime is 86 µs, or long triplet lifetime, which is suggested to belong to 
mTHPP remaining inside the PLGA nanoparticles. This result brings important 
information: mTHPP can be attracted from PLGA nanoparticles and attached to 
plasma protein during the drug administration via vessel injection. Other loading 
strategies, such as covalent conjugation, should be considered to prevent undesired 
releasing of drug outside tumor tissue. 
Triplet photosensitizer lifetime of mTHPP-PLGA nanoparticles in Jurkat cells 
indicates the intracellular decomposition of PLGA nanoparticles and drug release of 
mTHPP. Inside Jurkat cells, triplet lifetime of mTHPP after 5 h incubation is 3 µs, 
slightly longer than the value in liposomes. 
After 1 h incubation, mTHPP-PLGA has a triplet lifetime of 18 µs. This is much 
shorter than triplet lifetime of mTHPP-PLGA nanoparticles in water (70 µs). It 
exhibits the immediate start of drug releasing process after intracellular drug uptake. 
After 3 h and 5 h incubation, the triplet lifetime of mTHPP-PLGA decreases to 3.4 
and 3.2 µs, respectively. It exhibits the undergoing drug release of mTHPP from 
PLGA inside Jurkat cells. After 5 h incubation, the triplet lifetime (3.2 µs) of mTHPP-
PLGA in Jurkat cells almost equals the value of mTHPP (3.0 µs). After 24 h 
incubation, the triplet lifetime of mTHPP-PLGA is 2.7 µs, which is nearly unchanged 
when compared to the result of 5 h incubation. Such rapid drug release from PLGA 
nanoparticles has also been reported by Zeisser-Labouebe [2006]. A parallel 
investigation on mTHPC-PLGA gives a similar result (data not shown). This proves 
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6.7 Conclusions 
The photophysical behaviour of photosensitizer-loaded PLGA nanoparticles indicates 
that photosensitizer molecules encapsulate inside PLGA matrices and also attach on 
the surface. mTHPC has stronger tendency of photosensitizer-photosensitizer 
interaction inside PLGA matrices than mTHPP due to higher hydrophobicity caused 
by double bond degeneration. 
Similar to drug-loaded HSA nanoparticles, drug loading ratio is also an essential 
determination factor of photophysical properties and singlet oxygen generation of 
photosensitizer-PLGA nanoparticles. High loading ratio mTHPP- and mTHPC-PLGA 
nanoparticles generate less singlet oxygen than low loading ratio samples. 
When photosensitizer-loaded PLGA nanoparticles are dissolved in ethanol, PLGA 
nanoparticles decompose and release photosensitizers. After the photosensitizers are 
released, singlet oxygen can no longer be quenched by the residues of lactic acid and 
glycolic acid. 
Triplet lifetime of drug-carrier system offers information of drug-environment 
interaction, drug-nanoparticle binding, and in vitro microenvironment. Therefore, it 
can be utilized as an indicator for nanoparticles decomposition and drug release. 
Triplet lifetime of mTHPP-PLGA nanoparticles in aqueous solution is extremely long 
(more than 70 µs). mTHPP-PLGA nanoparticles in cell culture medium RPMI 
containing protein (FCS Albumin) have two triplet lifetimes: long time (86 µs), 
representing mTHPP still entrapped in PLGA matrices, and short time (7.9 µs), 
relating to mTHPP adsorbed on plasma protein. This result indicates that hydrophobic 
drug may have leaked out of PLGA matrices into plasma. The problem could be 
solved via covalent conjugation between drug molecules and PLGA matrices. 
The triplet lifetime of mTHPP-PLGA nanoparticles in Jurkat cells exhibits a 
decreasing tendency with incubation time. The decreasing triplet lifetime indicates 
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7. Comparison between PLGA and HSA nanoparticles 
PLGA and HSA nanoparticles are both potential biodegradable drug carriers. 
Hydrophobic drugs can be loaded via different strategies. Drugs are adsorbed or 
conjugated on the surface of HSA nanoparticles. In PLGA nanoparticles, drugs are 
encapsulated inside PLGA matrices. Which nanoparticle can deliver drug into tumour 
cells effectively and achieve rapid drug release? To answer this question, singlet 
oxygen generations of mTHPP-PLGA and mTHPP-HSA nanoparticles both in 
solution and in cells are compared in this chapter. 
 
7.1 Singlet oxygen generation of mTHPP-PLGA and mTHPP-HSA in solution 
mTHPP is a photosensitizer with high singlet oxygen quantum yield. However, singlet 
oxygen generation during drug transportation can be avoided if mTHPP is attached to 
large carriers such as nanoparticles. Singlet oxygen generation experiment in solution 
is verification whether mTHPP attachment to PLGA and HSA NPs remarkably 
decrease Φ∆ or not. 
Singlet oxygen generation results of mTHPP-PLGA and mTHPP-HSA nanoparticles 
in D2O are shown in Fig. 7.1 and Table 7.1. 



























Fig. 7.1. Singlet oxygen generation of mTHPP-PLGA and mTHPP-HSA in D2O, OD=0.2; 
excitation at 545 nm 
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 Φfl 1  τΤ (µs) 
2 τ∆1 (µs) 3  τ∆2 (µs) 
3  Φ∆ 3 
mTHPP 1 0.31 ± 0.01 - - 0.63 ± 0.06
mTHPP-PLGA 0.38 ± 0.01 9.5 ± 0.2 6.1 ± 0.5 (86%) 74 ± 6 (14%) 0.05 ± 0.03
mTHPP-HSA 0.40 ± 0.01 46 ± 5 - 29 ± 7 0.07 ± 0.03
Table 7.1. PDT-correlated photophysical properties of mTHPP-PLGA and mTHPP-HSA 
nanoparticles 
1λexc: 506 nm; fluorescence quantum yield: relates to mTHPP 
2Triplet lifetime was measured under normal air condition; λexc: 545 nm; λobs: 488 nm 
3Singlet oxygen measurement: mTHPP in ethanol, mTHPP-PLGA, and mTHPP-HSA in D2O, 
λexc: 545 nm 
 
From Table 7.1, mTHPP-PLGA nanoparticles have two singlet oxygen lifetimes in 
D2O. Most of singlet oxygen molecules (86%) have shortened singlet oxygen lifetime, 
τ∆1 (6.1 µs), which indicates strong quenching. This lifetime is supposed to be 
generated by mTHPP entrapped inside PLGA matrices. τ∆2 is 74 µs, which means 
singlet oxygen without quenching. However, the part of these singlet oxygen 
molecules is small (14%). This relates to singlet oxygen generated from PLGA 
surface. mTHPP-HSA nanoparticles have only one singlet lifetime since all mTHPP 
molecules are adsorbed on the surface of HSA nanoparticles. The difference between 
singlet oxygen quantum yields of mTHPP-HSA nanoparticles (0.07) and that of 
mTHPP-PLGA nanoparticles (0.05) is negligible. 
 
7.2 Behaviour of mTHPP-PLGA and mTHPP-HSA nanoparticles in Jurkat cells 
Biodegradable PLGA nanoparticles simultaneously decompose in surface and inside 
the matrix. For this reason, the drug release process is rapid [von Burkersroda 2002]. 
In contrast, the design idea of HSA nanoparticles is to obtain stability during long-
term storage. To achieve this, glutaraldehyde cross-linker is used. Could HSA quickly 
degrade inside targeting cells and release photosensitizers? To answer this question, 
intracellular singlet oxygen luminescence from PLGA and HSA NPs in Jurkat cells is 
measured, as shown below. 
Singlet oxygen generation results of mTHPP-PLGA and mTHPP-HSA nanoparticles 
in Jurkat cells are shown in Fig. 7.2 and Table 7.2. 
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Fig. 7.1. Singlet oxygen luminescence in cells. Cell line: Jurkat cells; incubation time: 5 h; 
mTHPP conc.: 3 µM; λexc: 532 nm 
 
 τTair (µs) 1 τTair (µs) ± 0.1 2 τ∆ (µs) ± 0.05 Φ∆ 3 ± 30% 
mTHPP 3.0 ± 0.1 4.0  0.80 100% 
mTHPP-PLGA 3.2 ± 0.2 4.1 1.05 114% 
mTHPP-HSA 5.9 ± 0.6 4.5 0.70 28% 
Table 7.2. Singlet oxygen generation from mTHPP, mTHPP-PLGA and mTHPP-HSA in 
Jurkat cells  
1Triplet lifetime of photosensitizer obtained from laser flash photolysis under normal air 
condition 
2Triplet lifetime of photosensitizer obtained from singlet oxygen luminescence data fitting 
3Relates to mTHPC in Jurkat cells 
 
Unlike their Behaviour in solution, mTHPP-PLGA nanoparticles generate four fold 
more singlet oxygen luminescence intensity inside Jurkat cells compared to mTHPP-
HSA nanoparticles after 5 h incubation. This is induced by possible two reasons. First, 
the intracellular decomposition rate of HSA nanoparticles is slower than PLGA 
nanoparticles since HSA nanoparticles are bound via covalent glutaraldehyde cross-
linking. This is contrary to the fact that PLGA matrices are formed by 
hydrophobic/hydrophilic interaction. Second, the amount of HSA nanoparticles taken 
up by Jurkat cells is possibly smaller than that of PLGA nanoparticles [Preuß 2010]. 
Due to their faster drug release inside cells, PLGA nanoparticles should be further 
investigated in vivo, possibly in a clinical setting. 
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7.3 Conclusions 
Singlet oxygen quantum yields of photosensitizer-loaded PLGA and HSA 
nanoparticles in solution are similar and very low. An in vitro experiment 
demonstrates that PLGA generates more singlet oxygen than HSA in cells after 5 h 
incubation. Drug encapsulation inside PLGA matrices results in faster drug release in 
tumour cells. PLGA NPs is superior to HSA NPs in terms of rapid drug release. 
However, it was proven in Chapter 6 that PLGA NPs can release the PS to serum 
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8. PLGA- and HSA-NPs as carriers for active tumour targeting 
In Chapters 5 and 6, photophysical properties as well as singlet oxygen generation in 
vitro of biodegradable HSA and PLGA nanoparticles for passive tumour targeting 
were discussed. Intracellular singlet oxygen luminescence from photosensitizer-
loaded HSA nanoparticles has only 25% of the luminescence intensity when 
compared to free photosensitizers. This result is supported by intracellular uptake and 
phototoxicity [Preuß 2010]. 
Passive tumour targeting, such as EPR effect, functions only on tissue level. To 
enhance photosensitizer accumulation in single cells and achieve active tumour 
targeting, photosensitizer-antibody conjugation was tested [Jiang 1990]. Enhanced 
photosensitizer accumulation in targeting cells was reported both in vitro and in vivo 
experiments [Berki 1992, Gutowski 2001]. However, direct conjugation of antibody 
to photosensitizer reduces cutaneous phototoxicity [Van Dongen 2004]. The 
hydrophobicity of photosensitizer severely influences the physicochemical properties 
of the antibody, which changes pharmacokinetics and biodistribution [Pelegrin 1991, 
Vrouenraets 2000]. These problems can be avoided if photosensitizers are conjugated 
to antibody-modified nanoparticles. In this chapter, photosensitizer-loaded 
biodegradable nanoparticles designed for active tumour targeting are studied. 
 
8.1 Covalently conjugated and antibody modified mTHPC-HSA nanoparticles 
Compared to drug adsorbed loading strategy, covalent conjugation offers a more 
stable drug loading during long-term storage and administration via blood vessel, as 
well as more controllable drug release [Kreuter 2007]. Nanoparticle surface 
modification with polyethylene glycol (PEG) can enhance the solubility of HSA 
nanoparticles in hydrophilic environment [Lin 1999]. Furthermore, HSA nanoparticles 
conjugated with antibodies are utilized to target certain cell types [Steinhauser 2006]. 
PEG shell is used to modify HSA nanoparticle surface because of its hydrophilicity 
and biocompatibility [Cheng 2007, Li 2007]. 
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8.1.1 Sample description 
Cetuximab-conjugated mTHPC-HSA nanoparticles targeting the epidermal growth 
factor receptor (EGFR) are named CePC-HSA. IgGPC-HSA is mTHPC-HSA 
nanoparticles modified by another antibody, IgG. CoPC-HSA is formed via mTHPC 
covalently bound to HSA nanoparticles. The dispersion media for mTHPC-HSA 
samples is distilled water. 
mTHPC-HSA nanoparticles descriptions are given in Table 8.1. 
 
Lr [µg/mg] Samples Ls  
mTHPC Cetuximab IgG 
CePC-HSA Adsorptive 20.3 15.0669 - 
IgGPC-HSA Adsorptive 21.0 - 13.9573 
CoPC-HSA Covalently binding 20.6 - - 
Table 8.1. Sample description of surface modified mTHPC-HSA nanoparticles 
Ls: loading strategies; Lr: loading ratio 
 
8.1.2 Absorption and steady-state fluorescence 
To investigate the influence of antibodies and PEG modification on ground state 
photosensitizer molecules, absorption spectra of surface-modified mTHPC-HSA 
nanoparticles were taken. 
Absorption spectra of mTHPC-HSA after scattering correction are shown in Fig. 8.1. 





















Fig. 8.1. UV-vis absorption spectra of mTHPC in ethanol and mTHPC-HSA in aqueous 
solution, scattering corrected 
 
8. PLGA- and HSA –NPs as carriers for active tumor targeting 
97
The Soret band maximum of CePC-HSA and IgGPC-HSA has a bathochromic shift to 
425 nm compared to that of mTHPC (417 nm). The Soret band maximum of CoPC-
HSA locates at 424 nm. The absorption of CePC-HSA and IgGPC-HSA at Soret band 
is equal to mTHPC, which means that antibody conjugation does not reduce the 
absorption of mTHPC. The absorption extinction of CoPC-HSA, however, is only 1/3 
compared to mTHPC. 
Fluorescence spectra of mTHPC and mTHPC-HSA are shown in Fig. 8.2. 

























Fig. 8.2. Fluorescence spectra of mTHPC in ethanol and mTHPC-HSA in aqueous solution. 
λexc: 506 nm 
 
The fluorescence maximum of the S1,0→S0,0 in mTHPC-HSA shifts to 657 nm 
compared to 654 nm of mTHPC. The fluorescence quantum yields of CePC-HSA and 
IgGPC-HSA are approximately 24.9% and 21.4% compared with mTHPC, 
respectively. The differences of ΦFL between CePC-HSA and IgGPC-HSA are 
negligible. The ΦFL of CoPC-HSA is much lower when compared to other samples. 
 
8.1.3 Fluorescence kinetic parameters 
The differences between absorption and steady-state fluorescence of Cetuximab- and 
IgG-loaded mTHPC-HSA NPs are negligible. The strong reduction of the 
fluorescence quantum yield is a proof of an interaction between mTHPC molecules 
and surrounding substances. Fluorescence lifetimes determined with TCSPC should 
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help further clarify this issue. 
Fluorescence lifetimes and their amplitudes of mTHPC in ethanol and mTHPC-HSA 
in aqueous solutions are shown in Table 8.2. 
 
 ΦFLa τ1 (ns) ± 0.1 / 
A [%] 
τ2 (ns) ± 0.1 / 
A [%] 
τ3 (ns) ± 0.05 / 
A [%] 
χ2 
CePC-HSA 24.9% 3.9 / [23.0] 1.5 / [45.5] 0.30 / [31.5] 1.09 
IgGPC-HSA 21.4% 3.6 / [19.8] 1.4 / [44.8] 0.29 / [35.4] 0.96 
CoPC-HSA 9.3% 3.3 / [22.9] 1.3 / [43.4] 0.26 / [33.7] 1.09 
Table 8.2. Fluorescence lifetime of mTHPC-HSA nanoparticles in H2O; λexc: 532 nm; λobs: 
650 nm; ΦFL: fluorescence quantum yield. a: Standard: mTHPC in ethanol; mTHPC conc. 3 
µM 
 
The fluorescence lifetime of mTHPC monomers in ethanol is 8.5 ns. The fluorescence 
spectra of mTHPC-HSA adsorptive nanoparticles consist of three fluorescence 
lifetime species. All three samples have similar fluorescence lifetimes with the same 
amplitudes. This means that antibody modification and covalent conjugation do not 
change the fluorescence lifetime of mTHPC-HSA nanoparticles. The dominant 
interaction mechanism of antibody-modified mTHPC-HSA NPs remains between 
mTHPC and HSA in spite of additional antibody conjugation. 
 
8.1.4 Singlet oxygen generation and laser flash photolysis 
The results above show that antibody modification has no influence on PS in ground 
state and excited singlet state. The information about antibodies interaction with 
singlet oxygen, however, is still missing. Singlet oxygen luminescence determination 
together with laser flash photolysis is conducted in order to investigate singlet oxygen 
generation of antibody-modified mTHPC-HSA NPs in solution. 
Singlet oxygen and triplet lifetimes of mTHPC-HSA in D2O are shown in Table 8.3. 
 
 τTair [µs] τTN2 [µs] fET τ∆ [µs] Φ∆ (±0.02) 
CePC-HSA 35 ± 3 98 ± 7 0.64 8 ± 1 0.09 
IgGPC-HSA 36 ± 3 103 ± 8 0.65 7 ± 1 0.08 
CoPC-HSA 29 ± 3 103 ± 8 0.72 6 ± 1 0.08 
Table 8.3. PDT-relevant photophysical parameters of mTHPC-HSA samples: triplet lifetime 
under normal condition τTair, Singlet oxygen lifetime (τ∆), and quantum yield (Φ∆) 
aAll samples were excited at 652 nm in singlet oxygen measurement. TPPS in D2O is taken as 
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the singlet oxygen quantum yield standard (Φ∆ = 0.70). 
 
The triplet lifetime under normal air condition τTair is mainly determined by cross-
linkage and independent of drug loading ratios or antibody modification. The samples 
CePC-HSA and IgGPC-HSA share the same value of τTair with mTHPC-loaded 100% 
cross-linked HSA NPs without any modification (Chapter 5). However, covalently 
conjugated sample CoPC-HSA has shorter τTair than drug adsorbed samples, which 
indicates a different microenvironment caused by loading strategy. The singlet oxygen 
lifetime τ∆ of the three samples is much shorter when compared with unmodified 
mTHPC-HSA nanoparticles (Chapter 5). This means that strong quenching of singlet 
oxygen caused by antibody modification and covalent conjugation occurs. 
 
8.1.5 Singlet oxygen luminescence detection in cells 
Unmodified mTHPC-HSA nanoparticles generate tiny amounts of singlet oxygen in 
cells after 5 h incubation (Chapter 5), which makes HSA nanoparticles unsuitable as 
rapid drug deliver carriers. Will surface modified mTHPC-HSA nanoparticles perform 
better? To investigate this, Jurkat and HT-29 cells were incubated for 5 h with 3 µM 
mTHPC and mTHPC-HSA nanoparticles in darkness, respectively. The singlet oxygen 
luminescence of photosensitizers located inside Jurkat and HT-29 cells was 
determined with the equipment described in Chapter 3. Data of intracellular singlet 
oxygen luminescence of mTHPC-HSA in Jurkat cells and HT-29 cells are shown in 
Table 8.4. 
 
 Jurkat cells 
 τ∆ [µs] ± 0.05 τT [µs] ± 0.1 Ι∆ a ± 30% 
mTHPC 0.65 3.6  100% 
CoPC-HSA 0.40 3.8 48% 
CePC-HSA 0.45 3.7 56% 
PEGPC-HSA 0.50 2.8 99% 
 HT-29 cells 
mTHPC 0.55  2.8  100% 
CoPC-HSA 0.45 3.1 25% 
CePC-HSA 0.45 2.7 76% 
PEGPC-HSA 0.40 2.7 84% 
Table 8.4. Singlet oxygen lifetime and triplet decay of mTHPC and mTHPC-HSA in cells 
after 5 h incubation; mTHPC Conc. 3 µM; cell number: 5×105 cells/ml; illumination time: 20 
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s; λexc: 652 nm; laser power: 1.5 mW 
aRelates to mTHPC in Jurkat cells 
bRelates to mTHPC in HT-29 cells 
 
All mTHPC-HSA nanoparticles generated singlet oxygen in both two types of cell 
lines after 5 h incubation. For CoPC-HSA without any modification, the luminescence 
intensity is less than 50% compared to mTHPC in Jurkat cells. In HT-29 cells, this 
value is only 25% of mTHPC. The singlet oxygen luminescence intensity of CePC-
HSA is three fold compared to CoPC-HSA (76% to 25%) in HT-29 cells. This may 
become evidence of EGFR targeting by monoclonal antibody Cetuximab. The Jurkat 
cells have no EGFR. Thus, no targeting effect was observed. However, better 
intracellular uptake enhancement against antibody modification can be obtained when 
PEG modification is used. The singlet oxygen luminescence intensity of PEGPC-HSA 
generated in Jurkat cells is equal to the value of mTHPC. The enhanced intracellular 
singlet oxygen generation induced by PEG modification is independent on cell line. In 
HT-29 cells, intensity of singlet oxygen luminescence also achieves a high level (84%) 
compared to mTHPC. 
 
8.2 Investigation on mTHPC-PLGA nanoparticles modified with antibodies 
In Chapter 6, the comparison of photosensitizer-loaded PLGA and HSA nanoparticles 
showed that unmodified PLGA nanoparticles perform well in transporting drugs into 
cells and rapidly releasing them. 
In the last section, photophysical properties of surface-modified HSA nanoparticles, 
as well as their capabilities of intracellular singlet oxygen generation, were 
investigated. Antibody and PEG modification were proved to be efficient, especially 
for HSA nanoparticles accumulation in HT-29 cells. In this section, the photophysical 
properties and intracellular singlet oxygen generation of surface-modified mTHPC-
PLGA nanoparticles are compared to examine if surface modification also enhances 
singlet oxygen generation in targeting cells. 
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8.2.1 Sample description 
mTHPC-PLGA nanoparticles were prepared with standard emulsion-diffusion-
evaporation method mentioned before. ErbPC-PLGA was modified with antibodies 
Erbitux. IgGPC-PLGA was modified with antibodies human IgG as control sample. 
mPEGPC-PLGA contained surface-adsorbed antibodies Erbitux and modified with 
mPEG shell. 
 
Lr (µg/mg) Samples 
mTHPC Erbitux IgG 
mTHPC-PLGA 64.150 - - 
ErbPC-PLGA 52.806 2.517 - 
IgGPC-PLGA 49.144 - 2.886
mPEGPC-PLGA 54.331 0.2093 - 
Table 8.5. Description to mTHPC-PLGA nanoparticles. Lr: loading ratio 
 
8.2.2 Absorption and steady-state fluorescence 
The absorption spectra of mTHPC in ethanol and mTHPC-PLGA in aqueous solution 
are shown in Fig. 8.3. 





















Fig. 8.3. UV-vis absorption spectra of mTHPC in ethanol and mTHPC-PLGA nanoparticles in 
aqueous environment. mTHPC Conc. 4 µM. The absorption spectra of mTHPC-PLGA are 
shown after scattering correction. 
 
The Soret band maxima of all mTHPC-PLGA samples show a bathochromic shift 
compared to mTHPC spectrum. The Soret band maximum of mTHPC in ethanol 
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locates at 417 nm. The Soret band maxima of four mTHPC-PLGA samples are shifted 
to 425 nm. The strongest Q band of mTHPC absorption spectrum locates at 650 nm. 
Its counterpart of mTHPC-PLGA shifts to 652 nm. Surface modification causes no 
additional change to absorption mTHPC-PLGA nanoparticles. 
The steady-state fluorescence of mTHPC and mTHPC-PLGA was excited at 506 nm. 
Fluorescence spectra of mTHPC and mTHPC-PLGA are shown in Fig. 8.4. 

























Fig. 8.4. Steady-state fluorescence of mTHPC and mTHPC-PLGA; λexc: 506 nm, data 
normalized 
 
The fluorescence peak of mTHPC locates at 652.5 nm. The fluorescence peaks of four 
mTHPC-PLGA samples are at 654.5 nm. The relative fluorescence quantum yields of 
mTHPC-PLGA nanoparticles (compared to mTHPC) are shown in Table 8.6. 
 
8.2.3 Fluorescence kinetic parameters 
Fluorescence decay times and their amplitudes are shown in Table 8.6. 
 
 ΦFL a τ1 [ns] ± 0.05/A 
[%] 
τ2 [ns] ± 0.02/A 
[%] 
χ2 
mTHPC-PLGA 3.5% 0.31/15.6 0.12/84.5 1.3 
ErbPC-PLGA 5.3% 0.35/12.9 0.14/87.1 0.94 
IgGPC-PLGA 5.2% 0.38/11.1 0.15/88.9 1.01 
mPEGPC-PLGA 5.0% 0.35/17.0 0.14/83.0 0.96 
Table 8.6. Fluorescence lifetime of mTHPC-PLGA in aqueous solution 
aΦFL Fluorescence quantum yield relative to mTHPC. λexc: 532 nm; λobs: 650 nm 
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The total fluorescence signal of all mTHPC-PLGA samples consists of two lifetimes. 
Both the lifetimes and their amplitudes are very similar. The fluorescence lifetime 
result, as well as absorption and steady-state fluorescence, exhibit that surface 
modification does not influence the photophysical properties of mTHPC-PLGA 
nanoparticles. 
 
8.2.4 Singlet oxygen generation and laser flash photolysis 
Singlet oxygen and triplet lifetime results of mTHPC-PLGA nanoparticles are shown 
in Table 8.7. 
 
 τ∆ (µs) τTair (µs) Φ∆ (µs) ± 0.03 
mTHPC-PLGA 5.0 ± 0.5 59 ± 2 0.03 
ErbPC-PLGA 13 ± 1 77 ± 3 0.04 
IgGPC-PLGA 5.5 ± 0.5 87 ± 4 0.04 
mPEGPC-PLGA 6.0 ± 0.5 79 ± 4 0.05 
Table 8.7. Singlet oxygen lifetime τ∆, singlet oxygen quantum yield Φ∆ and triplet lifetime 
τTair of mTHPC-PLGA samples. Solvent: D2O; λexc: 545 nm. Rose Bengal in D2O is taken as 
the singlet oxygen quantum yield standard (Φ∆ = 0.75). Triplet lifetime: λexc: 652 nm; λobs: 
470 nm 
 
mTHPC-PLGA samples generate very small amounts of singlet oxygen in solution. 
The shortened singlet oxygen lifetime indicates that singlet oxygen generated from 
mTHPC-PLGA is strongly quenched. The triplet state quenching rate constant kq of 
mTHPC-PLGA is in the order of 109 M-1s-1. This illustrates that the energy transfer 
between triplet state photosensitizer and molecular oxygen is inefficient. The triplet 
lifetimes of surface-modified mTHPC-PLGA are even longer than the unmodified 
sample. The reason should be the reduced exposure of triplet state mTHPC to solvent 
caused by additional PEG shell and antibodies [Lang 2004]. 
 
8.2.5 Singlet oxygen luminescence in HT-29 cells 
Singlet oxygen luminescence generated by mTHPC and mTHPC-PLGA nanoparticles 
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 τ∆ [µs] ± 0.05 τTair [µs] ± 0.1 Ι∆ a ± 30% 
mTHPC 0.75  3.8  100% 
mTHPC-PLGA 0.65 3.1 106% 
ErbPC-PLGA 0.60 3.5 76% 
IgGPC-PLGA 0.55 3.3 87% 
mPEGPC-PLGA 0.60 2.8 69% 
Table 8.8. Singlet oxygen generation of mTHPC and mTHPC-PLGA in HT-29 cells. 
Incubation time: 5 h; mTHPC Conc. 3 µM; cell number: 5×105 cells/ml; illumination time: 20 
s; λexc: 652 nm; laser power: 1.5 mW 
amTHPC in HT-29 cells was taken as standard 
 
Unmodified mTHPC-PLGA has the same value of singlet oxygen luminescence with 
mTHPC in HT-29 cells after 5 h incubation. mTHPC-PLGA nanoparticles modified 
with antibodies, as well as mPEG modified mTHPC-PLGA nanoparticles, show less 
singlet oxygen luminescence. Surface modification of PLGA nanoparticles exhibits no 
enhanced targeting effect to HT-29 cells containing EGFR receptors. This result 
illustrates that it is unnecessary to make surface modification to mTHPC-PLGA 
nanoparticles to enhance targeting effect since unmodified mTHPC-PLGA 




Intracellular singlet oxygen experiments exhibit that Cetuximab-modified mTHPC-
HSA NPs produces more singlet oxygen inside HT-29 cells when compared to 
unmodified mTHPC-HSA NPs. Cetuximab modification showed enhanced targeting 
effect on HT-29 cells containing EGFR factor in vitro. Besides antibody modification, 
PEGylated mTHPC-HSA nanoparticles exhibit enhanced uptake in both Jurkat and 
HT-29 cell lines. The enhanced intracellular singlet oxygen generation of PEGylated 
sample is probably caused by higher molecular weight, which leads more efficient 
endocytosis. PEG surface modification can be used alone to promote passive tumour 
targeting. Nevertheless, one should consider that this result is obtained only in the 
level of in vitro. 
The relative intensity of intracellular singlet oxygen luminescence of unmodified 
mTHPC-PLGA nanoparticles is similar to that of mTHPC. However, the luminescence 
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intensity of the three antibody-loaded mTHPC-PLGA samples is less than mTHPC 
and unmodified mTHPC-PLGA nanoparticles. The drug releasing mechnism of PLGA 
nanoparticles is drug diffusion through the polymer matrix [Mu 2003]. Surface 
modification may block the diffusion pathway. No benefit is evident from surface 
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9. Summary / Zusammenfassung 
The main goal of this PhD thesis is the photophysical investigation of biodegradable 
photosensitizer-nanoparticle carrier systems achieving passive and active tumour 
targeting strategies. For this purpose both steady state and time-resolved 
spectroscopic methods accompanied by data analysis were utilized. Especially 
time-resolved singlet oxygen luminescence generated from photosensitizer-loaded 
nanoparticles was detected both in solution and in vitro. 
Until now no publication was found that entirely investigates the influence of drug 
loading ratio on photophysical properties of photosensitizer-loaded nanoparticles and 
their intracellular singlet oxygen luminescence as well. The cross-linking of HSA NPs 
also needs to be evaluated in terms of photophysical characterization and singlet 
oxygen generation determination. 
 
This work contains three main parts: 
First the photophysical properties of Pheo-HSA nanoparticles were compared to free 
pheophorbide a. Steady-state and time-resolved fluorescence experiments have 
already proved that the interaction between pheophorbide a and HSA nanoparticles is 
strong. This interaction leads to low singlet oxygen quantum yield (0.07) in D2O 
compared to free Pheo (0.52) in ethanol. But when incubated in Jurkat and HT-29 cell 
lines, Pheo-HSA nanoparticles have been proved to generate singlet oxygen inside 
cells. This result coincides with intracellular uptake and phototoxicity experiments 
carried out by Preuß [Chen et al 2009]. They all reveal the capability of HSA 
nanoparticles to carry photosensitizers into tumour cells. 
 
In the second part the well-known photosensitizers mTHPP and mTHPC were loaded 
to HSA- and PLGA- nanoparticles. It was found that the loading ratio determines the 
photophysical properties of both photosensitizer-loaded HSA and PLGA nanoparticles. 
For HSA nanoparticles, photosensitizer-nanoparticle interaction is the preferential 
mechanism in low loading ratio sample. But in high loading ratio sample, 
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photosensitizer-photosensitizer interaction becomes the determining interaction. This 
interaction prevents singlet oxygen generation from high loading sample. For PLGA 
nanoparticles, high drug loading ratio also leads to a strong singlet oxygen quenching. 
At high drug loading ratio PLGA nanoparticles, some photosensitizer molecules may 
be localized deeply inside PLGA matrices and far away from surface. This induces a 
slower drug release since drug will diffuse through the polymer matrix during the 
release process [Mu 2003]. 
Controllable drug release in tumour cells can be achieved by adjusting the amount of 
cross-linking of HSA nanoparticles. 40% and 100% cross-linking HSA nanoparticles 
release drug in tumour cells faster than 200% cross-linking sample. The latter needs 
more than 24 h to decompose therefore it is not useful for rapid drug delivery. 
Pharmaceutical industry requires confirmed quantified drug loading parameters. 
Based on the loading ratio and cross-linking results of drug-loaded HSA NPs above, a 
comparable and repeatable preparation of mTHPC-HSA nanoparticles was fixed to be: 
20 µg / mg, 100% cross-linking. 
Compared to covalently conjugated HSA nanoparticles, PLGA nanoparticles 
decompose much faster since they are formed via hydrophobic / hydrophilic 
interaction. However, it brings another problem that photosensitizers encapsulated 
inside PLGA nanoparticles can be attracted by protein in cell cultural media before 
they are transported to targeting cells. For this reason, further in vivo evaluation of 
drug-loaded PLGA NPs is needed. 
The singlet oxygen quantum yields of photosensitizer-loaded PLGA and HSA 
nanoparticles in solution are negligible. For short period incubation (5 h), PLGA 
nanoparticles show 4 folds higher singlet oxygen luminescence than HSA 
nanoparticles. It is supposed that PLGA nanoparticles should be more hopeful carriers 
in terms of rapid drug release if photosensitizer can be covalently conjugated to 
PLGA matrices. 
 
In the third part of this work, active tumour targeting behaviour achieved by surface 
modification of HSA and PLGA nanoparticles has been tested. Intracellular singlet 
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oxygen measurement reveals that HSA nanoparticles, both with antibody and PEG 
surface modification have an enhanced targeting of tumour cells in vitro. 
On the contrary, such surface modifications of PLGA NPs result in reduced singlet 
oxygen generation in HT-29 cells. The reason is the blocking of drug diffusion 
pathway out of PLGA matrices by surface substituents. 
Another problem of antibody conjugation is to quantify the antibody number per 
nanoparticle. Moreover the use of antibodies as surface modification of nanoparticles 
for active targeting should be cautious when considering the limited impact and high 
costs. 
 
Further research on this issue should be oriented to several directions as follow: 
First of all, intracellular singlet oxygen detection can be used together with confocal 
laser scanning microscopy technique. Secondly, in vivo PDT experiments with 
photosensitizer-nanoparticle carrier system should be carried out based on the 
deep-going in vitro singlet oxygen determination. All in vitro and in vivo singlet 
oxygen results will feedback to promote the optimization of the preparation of 
photosensitizer-loaded nanoparticles. Finally, the stability of drug-loaded 
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Ziel der vorliegenden Arbeit ist die photophysikalische Untersuchung 
biodegradierbarer Photosensibilisator- beladener Nanopartikel als Transportsysteme 
für aktives und passives Tumor-Targeting. Zu diesem Zweck wurden sowohl 
stationäre, als auch zeitaufgelöste spektroskopische Methoden angewand. Speziell der 
durch mit Photosensibilisatoren beladenen Nanopartikeln generierte 
Singulettsauerstoff wurde mittels zeitaufgelöster Singulettsauerstofflumineszenz 
sowohl in Lösung als auch in vitro nachgewiesen. 
Bisher sind keine Veröffendlichungen zum Einfluss der Beladungsrate auf die 
photophysikalischen Eigenschaften von Photosensibilisator-beladenen Nanopartikeln 
und auf deren intrazelluläre Singulettsauerstofflumineszenz bekannt. 
Eine wichtige Untersuchung ist auch die des Einflusses der Quervernetzung von 
HSA-Nanopartikel auf deren photophysikalische Eigenschaften speziell auf die 
Fähigkeit Singulettsauerstoff zu generieren. 
 
Diese Arbeit besteht aus 3 Teilen: 
Der erste Teil beschäftigt sich mit der photophysikalischen Charakterisierung von 
Pheo-HSA-Nanopartikeln. Diese Untersuchungen wurden im Vergleich mit 
ungebundenen Phäophorbid a durchgeführt. 
Mittels stationärer und zeitaufgelöster Messungen konnte gezeigt werden, dass die 
Wechselwirkungen zwischen Phäophorbid a und den HSA-Nanopartikeln sehr stark 
ist. 
Diese Wechselwirkungen bewirken eine geringe Singulettsauerstoffquantenausbeute 
(0,07) in D2O verglichen mit dem von Phäophorbid a in Ethanol (0,52). 
Im Gegensatz dazu konnte nach der Inkubation in Jurkat- und HT-29-Zellen eine 
intrazelluläre Singulettsauerstoffgenerierung der Pheo-HSA-Nanopartikel 
nachgewiesen werden. 
Dieses Ergebnis wird auch durch Experimente zur intrazellulären Akkumulation und 
zur Phototoxizitäts, durchgeführt von A. Preuß [Chen et al 2009], bestätigt. Als 
Ergebnis der durchgeführten Untersuchungen kann die Schlussfolgerung gezogen 
werden, dass sich HSA-Nanopartikel sehr gut als Carrier für den Transport von 
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Photosensibilisatoren in Tumorzellen eignen. 
 
Im zweiten Teil wurden mit den Photosensibilisatoren mTHPP and mTHPC beladene 
HSA- und PLGA-Nanopartikel untersucht. 
Es konnte gezeigt werden, dass die Photosensibilisator-Beladungsrate die 
photophysikalischen Eigenschaften der HSA- und PLGA-Nanopartikel stark 
beeinflusst. 
Für die HSA-Nanopartikel dominieren bei geringen Beladungsraten die 
Wechselwirkungen zwischen HSA und den Photosensibilisatormolekülen. Mit 
steigender Photosensibilisator-Beladung spielen Wechselwirkungen zwischen den 
Photosensibilisatormolekülen eine zunehmende Rolle. Diese Wechselwirkungen 
verringern bei hoher Beladung der HSA-Nanopartikel die Generierung von 
Singulettsauerstoff. 
Die Geschwindigkeit der Freisetzung der Photosensibilisatoren kann mittels des 
Vernetzungsgrads der HSA-Monomere in den HSA-Nanopartikeln reguliert werden. 
40% und 100% vernetzte HSA-Nanopartikel entlassen die Wirkstoffe in Tumorzellen 
deutlich schneller als 200% vernetzte HSA-Nanopartikel. Letztere benötigen mehr als 
24 h um ihre Wirkstoffe freizusetzen, was für die klinische Verwendung nicht sinnvoll 
ist. 
Die pharmazeutische Industrie benötigt quantifizierte Baladungsparameter für 
Transportsystem wie Nanopartikel. Aufgrund der Ergebnisse bezüglich der 
Beladungsrate und Vernetzung der HSA-Nanopartikel konnte eine reproduzierbare 
Präparationsmethode entwickelt werden, zur Herstellung von HSA-Nanoparikeln, mit 
einer Beladungsrate von 20 µg / mg und einer HSA-Vernetzung von 100%. 
 
Auch für die PLGA-Nanopartikel konnte mit zunehmender Beladung ein verstärktes 
Singulettsauerstoffquenching nachgewiesen werden. 
Für stark beladene PLGA-Nanopartikel können die Photosensibilisatormoleküle nicht 
nur auf der Oberfläche sondern auch im inneren der Partikel lokalisiert sein. Diese 
Lokalisierung bewirkt eine Verzögerung der Freisetzung der Photosensibilisatoren 
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durch Diffusionsprozesse in den Nanopartikeln [Mu 2003]. 
Im Vergleich zu den kovalent verknüpften HSA-Nanopartikeln werden die durch 
hydrophobe und hydrophile Wechselwirkungen geformten PLGA-Nanopartikel 
deutlich schneller abgebaut. 
Jedoch besteht bei den PLGA-Nanopartikeln das die gebundenen 
Photosensibilisatoren eine starke Affinität zu den im Zellkulturmedium befindlichen 
Proteinen aufweisen. Dies könnte zur vorzeitigen Freisetzung der 
Photosensibilisatoren bei systemischer Verabreichung im Organismus führen. Daher 
wäre eine in vivo Untersuchung der Photosensibilisator –beladenen 
PLGA-Nanopartikel nötig. 
Die Singulettsauerstoffquantenausbeute der Photosensibilisator beladenen PLGA- 
Nanopartikel in Lösung ist wie auch schon für die HSA-Nanopartikel sehr gering. 
Nach kurzen Inkubationszeiten (5 h) in Zellen zeigen die PLGA-Nanopartikel eine 
4fach höhere Singulettsauerstoffluniniszenz als die HSA-Nanopartikel.  
Das Potenzial der PLGA-Partikel als Wirkstofftransporter in der Photodynamischen 
Therapie könnte deutlich gesteigert werden, wenn es zukünftig gelingt die 
Photosensibilisatoren kovalent an die PLGA-Matrix zu binden, um eine vorzeitige 
Freisetzung zu verhindern 
 
Im dritten Teil dieser Arbeit wurden, für aktives Targeting von Tumorzellen, 
Oberflächenmodifizierte PLGA- und HSA-Nanopartikel untersucht. 
Die intrazellulären Singulettsauerstoffmessungen weisen auf eine erleichterte 
Aufnahmein Tumorzellen von Antikörper- und PEG-modifizierten 
HSA-Nanopartikeln in vitro hin. 
Im Gegensatz dazu bewirkt solche Oberflächenmodifizierung bei 
PLGA-Nanopartikeln eine geringere Singulettsauerstoffgenerierung in HT-29-Zellen. 
Grund dafür ist die Blockierung der Diffusion der Wirkstoffe aus der PLGA-Matrix 
durch die Oberflächensubstituenten. 
Ein weiteres Problem der Antikörperkonjugation ist die Quantifizierung der 
Antikörpermenge je Nanopartikel. 
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Die Verwendung von Antikörpern als Oberflächenmodifizierung der Nanopartikel für 
aktives Targeting scheint sehr fraglich bezüglich des geringen Effekts und der damit 
verbundenen hohen Kosten. 
Zukünftige Arbeiten zu diesem Thema solten in unterschiedlicher Richtung erfolgen: 
Als erstes sollte die Singulettsauerstoffdetektion mit der Konfokalen Laserscanning 
Mikroskopie kombiniert werden; 
Weiterhin sollten in vivo PDT Experimente mit den Photosensibilisator-beladenen 
Nanopartikeln, basierend auf den umfangreichen in vitro 
Singulettsauerstoff-Untersuchungen angestrebt werden. 
Alle in vitro und in vivo Singulettsauerstoff-Untersuchungen können zur Optimierung 
der Präparation Photosensibilisator-beladener Nanopartikel beitragen. 
Letztendlich sollte in Langzeitstudien die Stabilistät der Wirkstoff-beladenen 
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